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ABSTRACT 
Alzheimer disease (AD) is a fatal neurodegenerative disorder characterized by the 
widespread deposition of proteinaceous plaques abundant in amyloid-β (Aβ) aggregates. 
Although the plaques mainly contain high molecular weight, insoluble Aβ fibrils, the low 
molecular weight soluble aggregates called oligomers have been shown as the primary 
toxic species responsible for synaptic dysfunction and neuronal loss in AD. The process 
of aggregation is nucleation-dependent, but also highly stochastic and inhomogeneous 
resulting in biophysically diverse assemblies. Recent advances in the field indicate a 
potential correlation between the phenotypic diversity observed in AD subtypes and 
aggregate polymorphism. Therefore, understanding the molecular mechanisms which 
lead to the generation of diverse Aβ oligomer structures (strains), and their subsequent 
propagation to polymorphic fibrils is crucial in establishing structure-phenotype 
correlations in AD. Our laboratory has previously characterized a specific Aβ oligomer 
called large fatty acid-derived oligomers (LFAOs), generated in the presence of fatty acid 
micelles. The work presented here has two main objectives: i) to determine the 
biophysical and biochemical properties of LFAOs in the context of strain behavior, 
particularly in the propagation of their structure; and ii) to determine the mechanism of 
oligomer strain generation by a family of lipids that are known to interact with Aβ. This 
work details the mechanism of LFAO strain propagation, which occurs in three 
distinctive phases involving a key intermediate. Also detailed is how LFAOs affect 
neuronal cells and selectively induce cerebral amyloid angiopathy (CAA) in transgenic 
AD mice brains, cementing the idea that distinct oligomer strains can influence AD 
phenotypes. Lastly, this work reveals that a family of Aβ oligomer strains can be 
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generated in interfacial conditions, suggesting that lipids present in the AD brain may 
play a role in strain generation. Overall, this brings forth fundamental mechanistic 
paradigms involved in oligomer strain generation and propagation that has invoked 
substantial insights into AD pathology. 
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CHAPTER I – INTRODUCTION, RATIONALE AND HYPOTHESES 
1.1 Alzheimer disease 
Alzheimer disease (AD) is a fatal neurodegenerative disorder characterized by a 
progressive and irreversible decline in the cognitive functions of the brain, resulting in 
acute memory loss. Recent statistics reveal that AD affects over 5.5 million people in the 
United States, and is the fifth-leading cause of death in individuals age 65 and older.1, 2 
The AD-inflicted brain is characterized by two pathological hallmarks: intracellular 
tangles of hyper-phosphorylated tau protein and extracellular plaques composed of the 
peptide amyloid-β (Aβ; Figure 1.1).3 While both of these lesions are found in postmortem 
AD brains, it is believed that the deposition of Aβ is the primary trigger of disease, with 
tau accumulation occurring secondarily.4 This was first postulated nearly three decades 
ago as the “amyloid cascade hypothesis” of AD pathogenesis.5-7 
 
 
Figure 1.1 Hallmarks of AD pathology  
Aβ plaques (a) and tau tangles (b) found in postmortem AD brains. Scale bars represent 125 (a) and 63 (b) μm, respectively. 
Reproduced from LaFerla et al.8 
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1.2 Cerebral amyloid angiopathy and AD 
  While the majority of AD cases are sporadic, a fraction of cases (5-10%) are 
familial, which occur in individuals having a genetic predisposition.3 The majority of 
these autosomal dominant missense mutations lead to increased production of Aβ, 
resulting in an early onset of disease symptoms.3 However, some mutations, such as the 
Arctic (E22G)9 and Italian (E22K)10 types, are known to induce a severe cerebrovascular 
disorder known as cerebral amyloid angiopathy (CAA).11-13 Affecting 80-90% of all AD 
patients,12, 13 CAA is caused by Aβ deposition within the cortical and leptomeningeal 
vessels of the brain,14, 15 which can lead to intracerebral hemorrhage and ischemic stroke. 
Taken together, it is clear that understanding the role of Aβ in the pathogenesis of both 
AD and CAA may lead to successful therapeutic intervention in disease progression. 
 
1.3 Aβ generation 
In 1984, Glenner and Wong were the first to isolate the subunit of proteinacious 
plaques from postmortem AD brains.16 At the time, they reported what is now known as 
Aβ to be found in two isoforms with nearly identical sequences, suggesting one to be a 
proteolytic cleavage product of the other. Later on, it was discovered that Aβ is produced 
by the sequential proteolysis of a larger transmembrane protein, called the amyloid 
precursor protein (APP), by β- and γ-secretases, respectively.17-20 APP is localized to the 
endoplasmic reticulum during translation, then post-translationally trafficked through the 
secretory pathway to the cell membrane.20 The processing of APP to produce Aβ can 
occur during intracellular trafficking, resulting in Aβ production in the lumen, or after 
trafficking to yield extracellular Aβ. While β-secretase cleavage occurs on the C-terminus 
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of position 671 in APP, the γ-secretase complex (minimally consisting of the proteins 
presenilin 1 or 2, nicastrin, presenilin enhancer 2, and anterior pharynx defective 1)21 
lacks specificity and depending upon the cleavage site, produces various isoforms of Aβ 
ranging between 38 and 43 amino acids in length (Scheme 1.1).18 Among these, the 
predominant isoforms found in extracellular plaques of AD brains are Aβ40 and Aβ42,3 
similar to what Glenner and Wong first reported. APP is ubiquitously expressed22 and 
processed in both neuronal and non-neuronal cells, producing Aβ constitutively in the 
plasma and cerebrospinal fluid of both healthy and diseased individuals throughout life.23, 
24 This leads to question the mechanism that Aβ undergoes which leads to toxicity in the 
AD-inflicted brain. 
 
 
Scheme 1.1 Proteolytic processing of APP by β- and γ-secretases 
Mutations in the Aβ sequence at position 22 involved in CAA are indicated in bold. 
 
1.4 Aggregation of Aβ 
The processing of APP releases Αβ as a single (monomeric) 38-43 amino acid 
long peptide. It has been well documented that monomeric Aβ has no organized 
secondary structure (randomly coiled), placing it in the class of intrinsically disordered 
proteins (IDPs).25, 26 Additionally, Αβ is particularly prone to a process of self-
 4 
association, or aggregation, in which monomeric units interact to form small multimers 
(oligomers) and eventually higher order aggregates (fibrils) that possess a distinct cross-
β-sheet structure.27-29 The aggregation and deposition of Aβ fibrils as senile plaques 
constitutes one of the hallmark pathologies observed in AD brains. In fact, protein 
aggregation and amyloid formation has been implicated in over 30 diseases,30 including 
Creutzfeldt-Jakob disease (CJD) and Parkinson disease (PD). Although these pathologies 
involve different amyloid-forming proteins, the parallel, in-register β-sheet structure of 
the amyloid fibril is conserved among them all.31, 32 Aβ amyloid formation follows a 
sigmoidal growth pattern similar to crystal growth with three distinct phases: the lag 
phase, growth phase, and saturation phase (Scheme 1.2).33, 34 The lag phase is 
characterized by the formation of a nucleus, followed by exponential growth via 
elongation and association of protein aggregates, and lastly saturation of high molecular 
weight (HMW), insoluble protein fibrils. The lag phase can be abrogated by ‘seeding’, 
which involves the addition of a pre-formed aggregate (seed) to the monomeric protein, 
resulting in augmentation of aggregation. While much has been revealed about the 
mechanism of protein aggregation, there still remains the question of which aggregate 
species (size/conformation) gives rise to toxicity in the AD brain.  
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Scheme 1.2 A schematic representation of Aβ aggregation 
Inset, a typical aggregate growth curve representing the lag, growth, and saturation phases. Adapted from Gosh et al.35  
 
1.5 Aβ oligomers and toxicity 
Initially it was believed that Aβ fibrils were the toxic species in AD, as they 
constituted the plaques observed in postmortem AD brains. However, the onset of AD 
symptoms in transgenic mice has been shown to occur well before the detection of 
fibrillar Aβ deposits,36, 37 suggesting that senile plaques might be ‘tombstones’ of the 
principle toxic events which occur in the etiology of disease.3 Along these lines, Fritschi 
et al. have recently reported that Aβ seeding potency in transgenic mice is highest at early 
stages of aggregation, and decreases with the onset of Aβ deposition.38 Erten-Lyons et al. 
further suggested the contribution of Aβ fibrils in AD toxicity to be insignificant when 
they revealed the presence of Aβ plaques in healthy individuals that had no signs of 
memory impairment.39 On the other hand, numerous reports have revealed that levels of 
soluble, oligomeric Aβ correlate closely with cognitive decline in AD.40-42 Additional 
reports have revealed that Aβ oligomers impair long term memory,43 target synapses and 
disrupt plasticity,44, 45 inhibit neuronal signal transduction,46, 47 and induce other 
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deleterious electrophysiological effects.48 Collectively, this suggests that Aβ oligomers 
are the primary cause of neuronal dysfunction and contribute significantly in the etiology 
of AD. This has resulted in an adapted version of the amyloid cascade hypothesis, termed 
the amyloid oligomer hypothesis.45 
 
1.6 Polymorphism in Aβ aggregation 
Although protein aggregation follows a conserved mechanism of growth, it is not 
a homogenous process by any means. In fact, protein aggregation involves a significant 
extent of heterogeneity, giving rise to a diversity of aggregate sizes and structural 
conformations, otherwise known as polymorphic structures. Polymorphism among Aβ 
fibrils has been shown to depend upon the growth conditions in vitro, such as 
temperature, pH, ionic strength, and even protein concentration.49-53 However, other 
reports have revealed the formation of polymorphic fibrils within a single in vitro 
reaction.54-57 Furthermore, fibril polymorphism has also been observed within the same 
tissue section of postmortem AD brains,58 as well as in Aβ derived from AD brain 
tissue.59, 60 Lu and co-workers generated fibrils from brain-derived Aβ in two AD patients 
and found that each case gave rise to a single predominant fibril structure, but those 
structures varied between each patient.60 Along similar lines, Cohen et al. have reported 
structural differences in Aβ from patients with varying phenotypes.59 They found that Aβ 
aggregates in patients who suffered from rapidly progressive AD (rpAD)61 were 
conformationally-distinct from Aβ aggregates in patients suffering from slowly 
progressing AD (spAD).59 This has been recently supported by others,62, 63 which 
collectively suggest that the heterogeneous nature of Aβ aggregation gives rise to a 
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multitude of unique and distinct conformations, which may lead to clinical and 
pathological phenotypes in AD.  
 
1.7 Prion protein propagation 
While the concept of structural polymorphism leading to phenotypic diversity has 
recently emerged in AD, it has long been observed in other neurodegenerative diseases, 
particularly prion diseases. In CJD, the prion protein (PrP) can adopt a multitude of 
misfolded, toxic conformations (scrapie prion, PrPSc) which recruit natively folded non-
toxic PrP (cellular prion, PrPC) to adopt the same PrPSc conformation through a templated 
mechanism of aggregation.64 The propagation of distinct PrPSc conformations, or 
‘strains’, from one host to another occurs with a high degree of structural fidelity and can 
be characterized by certain physiochemical traits such as incubation periods and rates of 
progression, as well as by specific patterns of neuropathological targeting and spreading 
(Scheme 1.3).64, 65 Along with cognitive decline and memory impairment, PrP strains can 
also be characterized by certain clinical manifestations, such as myoclonus, cerebellitis, 
and various psychiatric disorders.66 This leads to question if Aβ behaves similar to PrP in 
the induction of physiochemical, neuropathological, and clinical variances observed in 
AD. 
 
1.8 Prion-like propagation of Aβ 
Unlike PrP, Aβ is not known to be transmissible and infectious under normal 
conditions. However, Aβ does display several prion-like characteristics.52, 67, 68 These 
similarities include: i) Aβ and PrP both form misfolded aggregates rich in β-sheets31, 32 
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and display resistance to inactivation by heating, detergents, and proteases.69 
Furthermore, ii) both Aβ and PrP propagate their structures by seeding both in vitro and 
in vivo, and iii) can induce widespread pathology in the brain from a single inoculation 
site.70 Lastly, iv) Aβ and PrP both form polymorphic structures, which in the case of PrP 
clearly results in distinct phenotypes.49, 65 While polymorphic Aβ aggregates are 
hypothesized to be involved in such a phenotypic behavior in AD, as described earlier, it 
is not as well understood.  To this point, Condello and Stohr have proposed that the initial 
self-propagating Aβ assembly (i.e., strain) formed in the AD brain behaves as a prion, 
undergoing faithful propagation which governs the rate and pattern of neuropathology 
(i.e., phenotype; Scheme 1.3).71 If so, this would suggest that Aβ oligomer strains can 
propagate with high structural and biochemical fidelity to induce distinct phenotypic 
traits in the AD brain. Additionally, the important question of what factors influence or 
promote the generation of Aβ oligomer strains still remains.  
 
 
Scheme 1.3 Aβ strain propagation 
Factors influencing the generation of conformeric strains and a schematic representation of the physiochemical and neuropathological 
consequences of strain propagation. Figure inspired from similar review articles.71, 72 
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1.9 Interplay in Aβ strain generation 
Condello and Stohr suggest that the interplay of varying isoforms of Aβ (ranging 
in amino acid length) might be responsible for the generation of conformeric strains 
(Scheme 1.3).71 Others have shown that mutant isoforms of Aβ involved in CAA (such as 
Artic and Italian types) form distinct aggregate structures,73-78 suggesting that mutant 
isoforms of Aβ may play a role in strain generation (Scheme 1.3). While these genotypes 
do contribute to strain generation, the complexity is rather large considering that each 
isoform of Aβ (having the same amino acid sequence and length) can form a multitude of 
conformations depending on the environment and growth conditions (Scheme 1.3, shaded 
box). It is daunting to decipher the possibilities within the Aβ interactome, especially 
when considering hybrid strains formed via the interplay between strains. However, 
delineating the mechanisms underlying strain generation and propagation is paramount in 
understanding AD pathogenesis. 
 
1.10 Aβ strain generation within the cerebral microenvironment 
One area of particular interest is identifying the factors that contribute to strain 
generation that are not genotypic in origin (Scheme 1.3, shaded box). As discussed 
already, it is well known that reaction conditions can give rise to Aβ polymorphism in 
vitro; however, understanding how this occurs within the cerebral microenvironment of 
the AD brain (in vivo) is substantially more complex. While a wide range of factors may 
contribute to Aβ polymorphism in the AD brain, this work is focused on the role of 
membrane surfaces in generating polymorphs of Aβ. The plasma membrane contains 
certain subdomains, called lipid rafts, which are made up of a distinct composition of 
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proteins and lipids enriched in cholesterol and glycosphingolipids.79 Altered lipid 
metabolism, including lipid raft composition, has been shown to occur in the AD brain;80-
82 and it has been revealed that lipid deposits co-localize with Aβ plaques.83 This suggests 
that membrane lipid interfaces may play a role in catalyzing the generation of self-
propagating Aβ assemblies in the etiology of AD.84 
 
 
Scheme 1.4 Aβ misfolding and aggregation at GM1-rich lipid rafts  
Reproduced from Yagi-Utsumi et al.85 
 
1.10.2 Interfacial interactions in vivo 
In several reports by Yanagisawa and co-workers, a novel membrane-bound Aβ 
species was isolated from postmortem AD brains exhibiting early stages of disease 
pathology.86, 87 They revealed this Aβ species tightly bound to the ganglioside GM1, one 
of the most abundant gangliosides in the brain constituting a primary component of lipid 
rafts.88 It was later revealed that GM1 bound to Aβ with micromolar (μM) affinity89, 90 
and induced a β-sheet secondary structure transition.91-94 Collectively, this suggests that 
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Aβ may bind to GM1-rich lipid rafts and form a β-sheet template that can act as an 
endogenous seed to initiate aggregation (Scheme 1.4).86, 95-97 
 
1.10.3 Interfacial interactions in vitro 
In a broader sense, others have shown in vitro that Aβ binds and undergoes a 
structural transition to β-sheet in the presence of negatively-charged lipid bilayer vesicles 
(liposomes),98-100 and that binding is enhanced when membrane curvature is high.101 
Micelles, made up of spherical monolayers, have also been shown to stimulate Aβ 
aggregate formation. Rangachari et al. have shown the folding of Aβ42 into β-sheet rich 
oligomers in the presence of the micelle forming anionic surfactant, sodium dodecyl 
sulfate (SDS).102 Using another SDS-derived Aβ oligomer called globulomers, Barghorn 
et al. immunized mice to generate monoclonal antibodies that specifically recognized the 
oligomeric epitope.103 Using this monoclonal antibody, they detected the same epitope to 
be present in both transgenic mice and AD brains,103 indicating that Aβ oligomer 
conformations generated from in vitro reactions are relevant in vivo and may be viable 
models for investigating Aβ aggregation and strain generation in interfacial 
environments. 
 
1.11 Fatty acid-derived Aβ oligomers 
Similar to detergents, non-esterified fatty acids (NEFAs) also associate to form 
micelles at critical concentrations, which may provide a more physiological micellar 
system for analyzing Aβ aggregation and strain generation in interfacial environments. In 
fact, Kumar et al. have investigated this in detail over several reports, which has yielded 
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useful insight into this area of interest.104-106  Initially, Kumar and co-workers 
investigated the aggregation of Aβ42 in the presence of medium chain (C9:0 – C12:0) 
NEFAs at concentrations below, near, and above the critical micelle concentration 
(CMC).104  They found that below the CMC, NEFAs had no effect on Aβ42 aggregation. 
However, Aβ oligomers ranging in size from 12-18mers were observed by 
immunoblotting at concentrations near (just below) the CMC of each respective NEFA; 
while oligomers of 4-5 monomer units were observed at concentrations well above (3-5 
fold) the CMC. Both the 4-5mers and the 12-18mers persisted even after 10 days of 
incubation with NEFAs, as evident by imunoblotting. Furthermore, the 12-18mers 
formed by C12:0 NEFA could be isolated free of micelle association by size exclusion 
chromatography (SEC),104, 106 and were stable as an oligomeric species for up to 10 days. 
These 12-18mer oligomers were thusly-dubbed large fatty acid-derived oligomers, or 
LFAOs. Collectively, the data suggests that these oligomers are formed along an 
alternative pathway (“off-pathway”) that does not easily proceed toward fibrils (Scheme 
1.5), which is similar to what has been reported previously for SDS-derived oligomers.102, 
107 Given that oligomers are reported to be the primary neurotoxic species in the AD 
brain, this may have significant implications in AD pathology and warrants additional 
investigation. 
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Scheme 1.5 NEFAs promote alternative Aβ aggregation pathways 
Reproduced from Kumar et al.104 
 
1.12 Unique properties of LFAOs 
  A more detailed characterization of the morphology and size of isolated (free of 
micelle association) LFAOs by atomic force microscopy (AFM) revealed them to be 
spherical punctate dots with a bimodal height distribution ranging from 7-10 nm and 16-
19 nm.106 Analytical ultra-centrifugation experiments similarly revealed a bimodal 
distribution of disperse oligomers ranging from 56-110 kDa (12-24mers) in molecular 
weight.106 But perhaps the most interesting aspect of LFAOs was their behavior when 
seeded upon Aβ42 monomers. Rather than seeding towards fibril deposition, as what is 
typically observed,108 LFAOs underwent a self-propagative mechanism of replication that 
resulted in a quantitative amplification of oligomers, not fibrils.106 Illogically, the 
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efficiency of this process was inversely proportional to the seeding percentage; whereas 
increasing the amount of seeds from 0.2 to 20% (mole fraction) of LFAOs decreased the 
overall fold-increase of amplified oligomers.105 While the reasons for this are yet 
unanswered, this work revealed a novel self-propagating mechanism among certain Aβ 
oligomers. Kumar et al. proposed that these unique properties may arise due to the off-
pathway nature of LFAO formation, which arrests them as a kinetically-trapped species 
within a local energy minimum. Oligomers formed along such a pathway have an 
increased half-life as compared to their on-pathway counterparts, which results in a 
window where fibril-free, monomer-oligomer reactions can occur leading to oligomer 
amplification (Scheme 1.6).105, 106 Such a mechanism of templated corruption could 
explain several of the prion-like behaviors observed for Aβ, such as the spreading of 
toxicity from a single inoculation site in transgenic mice brains. Furthermore, faithful 
propagation of such oligomeric structures in vivo may be responsible for physiochemical 
and phenotypic differences in AD. Investigating the molecular details of this process may 
yield novel insight into the mechanisms of Aβ oligomer strain propagation and 
proliferation in AD.  
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Scheme 1.6 A schematic representation of LFAO replication 
The kinetically-trapped, off-pathway nature of LFAOs and its implications for mechanisms of self-propagative replication. 
Reproduced from Kumar et al.105 
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1.13 Rationale and Hypotheses 
  As presented above, understanding the role of Aβ oligomers in the etiology and 
pathogenesis of AD has become one of the focal points in this field of research. A large 
body of evidence suggests that polymorphic Aβ fibrils are responsible for the phenotypic 
diversity observed among AD cases. Fibrils are assembled from oligomeric building 
blocks, suggesting that polymorphic Aβ oligomers may govern phenotypic diversity in 
AD. However, the role(s) of conformational Aβ oligomer strains, and the molecular 
details and physiological consequences thereof, are lacking. Previous work by Kumar and 
others have shown that interfacial aggregation of Aβ along alternative pathways results in 
the generation of soluble Aβ oligomers with prion-like self-propagative properties.  
  Therefore, we hypothesize the following: 
  (i) LFAOs are a unique oligomer strain capable of undergoing a structurally 
and biochemically faithful process of propagation with distinct physiochemical and 
neuropathological effects.   
  (ii) LFAOs of wild-type Aβ42 can cross-propagate to induce oligomers of 
mutant isoforms of both Aβ40 and Aβ42 to generate novel hybrid Aβ oligomers.  
  (iii) Unique Aβ strains can be generated using other micelle- and liposome-
forming surfactants. 
  In the ensuing chapters, these hypotheses will be tested in order to provide insight 
into the molecular details of Aβ strain generation and propagation. First, factors 
governing the self-propagative replication (amplification) of LFAOs will be investigated 
in Chapter II in an effort to better understand the inverse relationship between replication 
efficiency and LFAO amount. Next, the prion-like faithful propagation of LFAOs and 
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consequences thereof will be examined in Chapter III, with insight into the kinetics of the 
process following in Chapter IV. In Chapter V, the ability of LFAOs to cross-propagate 
leading to hybrid oligomer formation will be evaluated. And lastly, the generation of 
other oligomer strains in micellar and liposomal conditions will be explored in Chapter 
VI before presenting the overall conclusions and future directions in Chapter VII. 
Chapter VIII will contain an exhaustive list of all materials and experimental procedures 
herein.  
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CHAPTER II – LFAO CONFORMATIONAL DYNAMICS 
2.1 Introduction 
As mentioned previously, LFAOs undergo a self-propagative replication in the 
presence of Aβ monomers that results in a quantitative increase in the amount of LFAOs. 
However, the efficiency of replication displays an inverse correlation to the amount of 
LFAO seeds.105 This leads to the question the molecular mechanism governing the 
efficiency of LFAO self-propagative replication. In this chapter, this was explored by 
investigating the concentration-dependent dynamics of LFAOs. The results obtained were 
initially disseminated by Dean et al. in the journal, Biochemistry,109 and are reproduced 
here with permission. 
 
2.2 Replication efficiency is inversely proportional to the initial concentration of 
LFAO seeds 
Replication efficiency as a function of initial LFAO seed concentration was 
investigated by initiating reactions with 0.5, 1, 3, 10, or 14 μM LFAO (O) seeds in the 
presence of a constant amount (50 μM) of freshly-purified Aβ monomer (A) at 25 °C in 
quiescent conditions. Replication efficiency was qualitatively determined using SDS-
polyacrylamide gel electrophoresis (PAGE) with immunoblotting (Figure 2.1f, inset) and 
quantitatively determined using SEC (Figure 2.1a-e) after 72 h of incubation. To 
determine the quantitative fold-increase (replication efficiency) of Os at each respective 
seed concentration, integration of the seeded reactions (Figure 2.1a-e, solid lines) were 
normalized against that of the seed alone (Figure 2.1a-e, dashed lines). Like previously 
observed,105 this yielded an inverse correlation with the seed concentration (Figure 2.1f). 
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The replication efficiency exponentially decreased from 6.1 to 2.6 as the O seed 
concentration increased from 0.5 to 3 μM, then reached a plateau of ~1.5 at 10 and 14 
μM, respectively (Table 2.1). An immunoblot of the corresponding reactions (Figure 2.1f, 
inset) revealed that upon replication, Os form disperse species ranging from roughly 56-
60 (single arrow) and 80-110 (double arrow) kDa, which corresponds to 12 and 24mers, 
respectively. The O seeds alone (odd-numbered lanes) interestingly revealed a 
concentration-dependent banding pattern. At low concentrations (0.5 and 1 μM), O seeds 
were predominantly 12mers (single arrow), while disperse 12-24mer bands (single and 
double arrow) were observed at concentrations above 1 μM. This suggests that LFAOs 
display concentration-dependent dynamics between 12mer and 12-24mer formations, 
which may influence the efficiency with which they replicate. 
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Figure 2.1 O replication efficiency  
(a-e) SEC chromatograms of O seeds alone (dashed) or after 72 h of incubation with 50 μM A (smooth) for 0.5, 1, 3, 10, and 14 μM 
seeds, respectively. (f) Quantitative fold-increase of Os at varying seed concentrations. Inset) A representative immunoblot of O 
replication reactions. For each O concentration, the left (odd) and right (even) lanes represent the seed and seeded reactions, 
respectively. Lane C represents 50 μM A alone after 72 h. The amount loaded into each well was kept constant at 34 ng for O seeds 
and seeded samples (based on the initial O concentration), while 3.4 μg was loaded for the A control (lane C). 
 
2.3 Detailed quantitative analysis of LFAO replication 
In order to more accurately quantify replication reactions, a simple equilibrium 
model was considered involving competing on- and off-pathways. The on-pathway was 
considered to lead to fibril (Fon) formation via self-nucleation of Aβ monomers not 
influenced by O seeds. The off-pathway was considered to be the pathway leading to 
replication of Os, as this has been shown previously to occur along an alternative 
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pathway.104-106 In a seeded reaction such as the one considered here, these reactions 
compete for A as such:  
𝑂 ⇄ 𝐴 ⇄ 𝐹𝑜𝑛 
Therefore, accounting for the amount of O, A, and Fon species should reveal more insight 
into these competing reactions. Upon incubation of Os with As after time t, the following 
reaction was utilized to quantify the amount of A: 
𝐴0 = 𝐴𝑐 + 𝐴𝑓 − 𝐴𝑑 
 Where A0 is the initial concentration at time 0, Ac is the concentration of monomer 
consumed by the on- and off-pathways, Af is the concentration of free monomer not 
consumed by either pathway, and Ad is the amount of monomer which partially 
dissociates from Os during SEC. To differentiate between Ac consumed along the on- and 
off-pathways, the following was considered: 
𝐴𝑐 = ∑(𝑂, 𝐹𝑜𝑛) = 𝐴′ + 𝐴′′ 
Where A′ represents the on-pathway leading to Fon and A′′ represents the off-pathway 
leading to amplified Os. To account for Ad, the linear proportionality between Ad and the 
O concentration (Figure 2.2m) was considered as follows:  
𝐴𝑑 = 𝑓([𝑂]) = (𝑠)[𝑂] + 𝑏 
Where s is the slope and b is the y intercept, respectively. Combining the above equations 
yielded: 
𝐴𝑓 = 𝐴𝑜 − (𝐴
′ + 𝐴′′) + [(𝑠)[𝑂0] + 𝑏] 
In a control reaction in the absence of O seeds (Figure 2.2k), this equation solved for A’ 
was defined as: 
𝐴′ = 𝐴0 − 𝐴𝑓 
 22 
Which upon analysis by integrating the SEC peaks (Figure 2.2k) yielded a value of ~6 
μM (Table 2.1) dedicated to the on-pathway in the absence of O seeds. In order to 
experimentally determine A” for seeded reactions, the following was considered: 
𝐴′′ = 𝑂𝑓 − 𝑂0 
Where Of is the final concentration of Os determined by SEC chromatograms of seeding 
reactions at 72 h of incubation (Figure 2.2a, c, e, g, and i). Plotting A” (also defined as 
the change in O, O) as a function of O0 yielded a positive exponential correlation (; 
Figure 2.2l and Table 2.1). Not considering the contribution of on-pathway aggregation, 
calculating Af (Af(c)) from the given values became: 
𝐴𝑓(𝑐) = 𝐴𝑜 − 𝐴
′′ − 𝐴𝑑 
Using the SEC results (Figure 2.2a, c, e, g, i) from replication experiments, the actual Af 
(Af(a)) values were determined, which are shown in Table 2.1. Given this, A’ was 
calculated for seeding reactions as: 
𝐴′ = 𝐴𝑓(𝑐) − 𝐴𝑓(𝑎) 
Which was found to be 5-6 μM committed toward the on-pathway, in good agreement 
with the experientially-determined value. Furthermore, plotting the net change in A (A) 
yielded an exponential decrease reciprocal to that of the net increase in Os (, Figure 
2.2l; Table 2.1). Considering that a constant amount of As were consumed along the on-
pathway, this suggests that as the amount of O seeds increased, more As were expended 
toward the off-pathway. Lastly, it is interesting that the amount of Os (O, Figure 2.2l) 
increased as a function of seed concentration, while replication efficiency (Of / O0; Figure 
2.1f) decreased. This may be due to conformational dynamics between 12 and 12-24mer 
formation, which requires more investigation. 
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Figure 2.2 Quantitative analysis of LFAO replication  
(a−k) Representative SEC chromatograms of reactions that were used to derive the parameters in Table 2.1. (a, c, e, g, and i) O seeds 
alone (dashed) or after 72 h of incubation with 50 μM A (smooth) for 0.5, 1, 3, 10, and 14 μM seeds, respectively. (b, d, f, h, and j) 
Reactions of 50 μM A alone at 0 h (smooth) or with 0.5, 1, 3, 10, and 14 μM O seeds, respectively (dashed). (k) A reaction of 50 μM A 
alone at 0 h (smooth) and 72 h (dashed) of incubation. (l) Net increase in O concentration upon replication (O; ) and net change in 
free A concentration (A; ) as a function of initial O concentration. The data represent an average of three independent trials. (m) 
Quantitation of O dissociation to A during SEC. The integrated A peaks (fractions 22-27) were normalized against a known A 
concentration (50 µM). 
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Table 2.1 Quantitative analysis of LFAO replication 
 
Data derived from SEC chromatograms of three individual replication experiments (denoted as *) shown in Figures 2.1 and 2.2 are 
summarized along with their standard deviations in parentheses. The results calculated from the experimental results are denoted as 
“”, while the known parameters are denoted as “”. The symbols Ao, O0, Of,  A”, Af(c), Af(a), A, and A’ are defined within the 
equations above and are described in the text. 
 
2.4 Insights into O conformations 
In order to better understand the unique conformational properties of Os, the extrinsic 
fluorescence dyes ANS (8-anilinonaphthalene-1-sulfonic acid) and DCVJ (9-(2,2-
diicyanovinyl)julolidine) were utilized to investigate O binding affinity. It has been well 
documented that ANS preferentially binds to solvent-exposed hydrophobic surfaces of 
proteins, which results in an increased fluorescence intensity and a blue shift in the 
emission maxima.110 The less established probe, DCVJ, has been recently reported to 
bind strongly to amyloid oligomers, resulting in increased fluorescence emission.111 
Therefore, fluorescence experiments were conducted with As, Os, and Fon in the presence 
of either ANS or DCVJ, respectively (Figure 2.3). Neither ANS nor DCVJ fluorescence 
was increased in the presence of As, as expected (, Figure 2.3a-b). Both dyes bound to 
Fon species (), albeit to a lesser degree as compared to Os (). ANS binding was 
marginally increased in the presence of Os, suggesting more solvent-exposed 
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hydrophobic surfaces. However, DCVJ binding to Os was roughly twice the amount as 
compared to Fon aggregates, which agrees with previous reports suggesting DCVJ to 
preferentially bind to amyloid oligomers.111 Collectively, these data indicate that the 
structure of O varies from that of the fibril structure, and warrants further investigation.  
 
 
Figure 2.3 Biophysical characterization of Os  
(a-b) ANS and DCVJ binding fluorescence, respectively, for As (), Os (), and Fon (). ANS and Aβ concentrations were kept 
constant at 100 μM and 6 μM, respectively. DCVJ and Aβ concentrations were kept constant at 10 μM and 5 μM, respectively. (c) 
FTIR of Os (smooth), Fon (dashed), and BSA (dash-dot). A total of 4096 accumulations were collected by scanning 1750 – 1550 cm
-1 
at a resolution of 2 cm-1. 
 
Previous reports by Kumar et al. have revealed that Os have a β-sheet secondary 
structure,104 however the characteristic of the β-sheets, either parallel or antiparallel, was 
not distinguished. As stated in the introduction, amyloid fibrils form a characteristic in-
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register parallel β-sheet structure,28, 29 and it is important to know if Os have a similar or 
dissimilar orientation. Fourier transform infrared spectroscopy (FTIR) has been shown to 
distinguish between parallel and antiparallel β-sheets due to subtle variations in amide 
bond stretching frequencies.112 Therefore, Os and Fon FTIR spectra were collected 
(Figure 2.3c), as well as a control sample of the known α-helical protein bovine serum 
albumin (BSA). As expected, the FTIR spectra of BSA contained an amide stretching at 
1655 cm-1 (dash-dot, Figure 2.3c), indicative of α-helical structure. In addition, stretching 
at 1626 cm-1 was observed in Fon aggregates (dashed line, Figure 2.3c), indicative of 
parallel β-sheets, similar to what has been reported previously.113, 114 The FTIR spectra of 
Os was similar to that of fibrils, suggesting that the oligomeric assembly is made up of 
parallel β-sheets (smooth line, Figure 2.3c). Interestingly, the presence of antiparallel β-
sheets at 1690 cm-1 was not observed in the FTIR spectra of Os, which is contrary to what 
has been observed for other amyloid oligomers.115-117 However, this is in agreement with 
our previous results that Os are detected by the fibril-specific conformational antibody, 
OC,105 suggestive of fibrillar oligomers.118, 119  
 
2.5 Concentration-dependent assembly of Os 
In order to further investigate the observed concentration-dependent size 
distribution of Os, immnoblotting was performed (Figure 2.4a). As observed previously, 
two distinct size distributions centered at 12 and 24mer Aβ species were observed at high 
concentrations (Figure 2.4a, 4-10 μM). Also as observed prior, the upper (double arrow) 
24mer band faded with decreasing O concentrations, suggesting a concentration-
dependent assembly of two individual 12mer (O) units. In order to eliminate the 
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possibility that this may be due to the presence of the SDS denaturant, a 10 μM O sample 
was electrophoresed under native conditions (lane N, Figure 2.4a), which revealed two 
oligomer distributions similar to what was observed in the presence of SDS. To 
investigate this further, the samples were subjected fractionation by SEC on a Superdex-
75 column. This revealed that 10 μM Os elute from the column at 8.67 mL, while 0.5 μM 
Os elute at a more inclusive volume of 8.79 mL (Figure 2.4b). In fact, plotting the elution 
volume of Os against the molar concentration revealed a decreasing sigmoidal trend, 
suggesting the formation of smaller sized oligomers at lower concentrations (Figure 2.4b, 
inset).  
 
 
Figure 2.4 Molecular size of Os  
(a) An immunoblot of 0.5, 1, 2, 4, 6, and 10 μM Os, respectively. The amount loaded onto each lane was maintained at 45 ng. Lane N 
represents a 10 μM (113 ng) O sample electrophoresed under non-denaturing conditions (without SDS). Single and double arrows 
represent O 12mer and 24mer band, respectively. (b) SEC elution profiles for 0.5 (smooth) and 10 (dashed) μM Os. Inset) Elution 
volumes for 0.5, 1, 3, 10, and 14 μM Os, respectively. 
 
To investigate the possibility of two individual 12mer Os associating to form a 
disperse 12-24mer, ANS binding was performed at varying concentrations of Os (Figure 
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2.5a-b). As the concentration of Os increased from 0.5 to 8 μM, an increase and blue shift 
in the emission maxima was observed (Figure 2.5a). The same data was collected for As 
and Fon as controls, which was processed by integration and normalization as shown in 
Figure 2.5b. ANS did not bind to As, similar to what has been presented above, and 
therefore did not show any concentration-dependent changes (, Figure 2.5b). Fon 
aggregates did bind ANS, but did not show any concentration-dependent changes upon 
dilution from 8 to 0.5 μM (, Figure 2.5b). However, Os did display concentration-
dependent ANS binding (, Figure 2.5b). Below 1 μM, Os bound ANS to a lesser degree, 
which then increased above the level of Fon aggregates upon increasing concentration. A 
transition such as this suggests conformational dynamics involving the solvent-exposed 
hydrophobic regions of oligomer assemblies. Upon fitting the O ANS data to a monomer-
dimer model (ie, 12mer to 24mer), a dissociation constant (Kd) of 0.1 uM was 
determined. 
Far-UV circular dichroism (CD) spectroscopy was then used to determine 
whether the observed conformational changes resulted in secondary structure changes 
(Figure 2.5). Os were evaluated at 0.5 and 8 μM, concentrations where they showed the 
greatest degree of variation in ANS binding. The minima observed at 217 nm, indicative 
of β-sheets, was identical for both 0.5 and 8 μM Os (Figure 2.5c). This is similar to the 
spectrum observed for fibrils (Figure 2.5d). However, since the solvent exposed 
hydrophobic content increased with an increase in LFAO concentration, which was not 
observed for fibrils, one could conclude that the dynamics involve tertiary or quaternary 
structure changes.  
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Figure 2.5 Conformational changes involving O dynamics  
(a) ANS scans of 0.5, 1, 2, 4, 6, and 8 μM Os along with 100 μM ANS blank (dashed). (b) ANS fluorescence scans from (a) were 
integrated and normalized against Aβ concentrations, which were then plotted for A (), O (), and Fon (). The data were fitted 
with a monomer-dimer equation given in the methods section. (c-d) CD spectra for 0.5 (smooth) and 8.0 (dashed) μM O (c) and Fon 
(d) samples. The perpendicular dotted line indicates 217 nm. 
 
2.6 Os also display concentration-dependent effects in cell culture 
In vitro cell culture assays were employed to assess the neurotoxicity of Os in 
human neuroblastoma SH-SY5Y cells. To investigate the ability of Os to induce 
apoptosis, the TdT-mediated dUTP nick-end labeling (TUNEL) assay was employed, 
which has been previously used to evaluate Aβ toxicity.120-122 Interestingly, the toxicity 
of Os was highest at 0.01 μM, and decreased with increasing concentrations of 0.1 and 1 
μM (Figure 2.6a and c). This inverse proportionality suggests that conformational 
dynamics may play a role in cellular activity, as it correlates well with the ANS binding 
and replication efficiency data. 
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Figure 2.6 O induced cellular apoptosis  
(a) Nuclear DAPI (blue) and TUNEL (green) stained images of SH-SY5Y cells following 24 h treatment with 0.01, 0.1, 1 μM Os 
along with (b) negative (CONT, buffer equivalent) and positive (25 μM H2O2) controls. Images are representative of 3−7 independent 
experiments. (c) Cellular apoptosis quantified using MATLAB functions applied to single-channel fluorescence microscope images. 
Results are reported as the fraction (TUNEL/DAPI) of apoptotic cells. ***p < 0.001 vs negative control. Error bars represent SEM, n 
= 3−7. 
 
To further investigate this unique activity in cell culture, the ability of Os to 
activate caspase enzymes was probed using a fluorescent inhibitor of caspases (FLICA) 
technique. In contrast to the apoptosis results, caspase activation was not found to be 
inversely proportional to O concentration. Rather, both 0.1 and 1 μM Os activated 
caspase to a high degree, whereas caspase activation by 0.01 μM Os was significantly 
decreased. These results suggest that O induced caspase activation may trigger non-
apoptotic pathways, as caspases are known to have a multitude of non-apoptotic cellular 
activities. In fact, three of the caspases utilized in this experiment are regulators of 
inflammatory immune response, not apoptosis.123 Regardless, it is clear from the 
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apoptosis data presented here that LFAO conformational transitions play a role in cellular 
activity.  
 
 
Figure 2.7 O induced caspase activation  
(a) Nuclear Hoechst (blue) and FLICA-labeled active caspase (green) stained images of SH-SY5Y cells following 24 h treatment with 
0.01, 0.1, 1 μM Os along with (b) negative (CONT, buffer equivalent) and positive (2 U/μL TNF-α) controls. Images are 
representative of 3−5 independent experiments. (c) Cellular caspase activation quantified using MATLAB functions applied to single 
channel fluorescence microscope images. Results are reported as the fraction (FLICA/Hoechst) of caspase activated cells. ***p < 
0.001 and **p <0.01 vs negative control; +p < 0.05 vs 0.01 μM O. Error bars represent SEM, n = 3-5. 
 
2.7 Conclusions 
Based on the results described above, we conclude that LFAOs are dynamic 
oligomeric species and show a concentration-dependent association of 12mers (56 kDa) 
to form diffuse 12-24mers (56-110 kDa). ANS binding revealed that LFAOs undergo a 
conformational reorganization upon dilution that does not result in β-sheet secondary 
structure reorganization, as shown by CD spectroscopy. Interestingly, this conformational 
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reorganization profoundly affected the ability of LFAOs to self-replicate in the presence 
of Aβ monomers. This is best shown by comparing the replication efficiency data from 
Figure 2.1f (, Figure 2.8) and the ANS binding data from Figure 2.5b (, Figure 2.8), 
which display near identical concentration-dependent responses. This further solidifies 
the relationship between conformational reorganization and replication efficiency.  
 
 
Figure 2.8 LFAO dynamics and replication efficiency show similar trends 
Comparison of replication efficiency (, derived from Figure 2.1f) and %12mer (, derived from Figure 2.5b) as a function of LFAO 
concentration. 
 
LFAO conformational dynamics also manifests in cellular activity, particularly in 
their ability to induce apoptosis in human neuroblastoma cells. Considering these aspects 
of LFAO behavior together, this data reveals the hypothetical model depicted in Scheme 
2.1. At low concentrations, LFAOs are primarily 12mers and display maximum 
replication efficiency and apoptotic activity (Figure 2.8). However, the association of 
12mers to 12-24mers at increased concentrations leads to negligible replication and 
apoptotic behavior, which poses to question if 12-24mer LFAOs may undergo a more 
 33 
conventional prion-type propagation leading to HMW fibrillar aggregates. This has been 
considered in detail and is the topic of Chapter III. Regardless, it is clear from the data 
presented here that concentration-dependent conformational dynamics between LFAO 
12mer and 12-24mer formation governs their ability to both replicate and induce 
apoptosis.  
 
 
Scheme 2.1 A schematic representation of LFAO dynamics revealed by this work and its 
consequences 
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CHAPTER III – LFAO PROPAGATION 
3.1  Introduction 
As described in the previous chapter, LFAO 12mers (Os) undergo replication 
when seeded upon Aβ monomers (As). However, only a modest level of replication 
occurs at high concentrations of LFAO seeds, where they exist as disperse 12-24mers 
(Ls). Considering Ls are ineffective seeds for replication, this leads to question the end 
result of seeding As with Ls. Particularly, do Ls seed HMW fibrils, and if so, will Ls 
manifest in the fibril structure and function? Investigation of this has yielded novel 
insights into the strain-like behavior of Aβ oligomers, which are reproduced herein from 
the published report by Dean et al. in Scientific Reports.124 
 
3.2  Inoculation of LFAO 12-24mers in TgCRND8 mice 
Inoculation of Aβ aggregate seeds in transgenic animals has been previously 
shown to undergo prion-like propagation, leading to widespread deposition throughout 
the brain.70 We were interested to know if introduction of LFAOs into the neonatal brain 
of an AD transgenic mice would yield similar results. Therefore, Ls (10 μM) were 
injected into the cerebral ventricles of newborn TgCRND8 mice (Figure 3.1), which 
overexpress the Swedish and Indiana mutants of human APP leading to amyloid 
pathology three months after birth.125 Parallel injection of As and Fon aggregates to the 
litter-mates were used as controls. Mice were euthanized at three months, and brains were 
extracted and analyzed for Aβ pathology. One hemibrain was used for visualization of 
Aβ plaques via immunostaining (Figure 3.1a-c), while the other hemibrain was used to 
quantify total Aβ amounts (Figure 3.1d). Compared to the buffer only control, L and Fon 
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administration resulted in an increased number of amyloid plaques throughout the cortex 
and hippocampus, as well as diffuse deposits along the anatomical structure of the 
hippocampus and the performant path (Figure 3.1a and d). Image analysis was used to 
quantify the total amyloid burden (Figure 3.1b), which was highest among mice injected 
with Fon, followed by Ls and As. However, a large number of Aβ positive vessels in the 
meninges and choroid were observed in mice injected with Ls (Figure 3.1a and c), 
leading to a profound amount of CAA pathology in these mice. This suggests that the 
unique structural conformation (i.e., strain) of LFAOs selectively induces the CAA 
phenotype in TgCRND8 mice. 
To quantify the total amount of Aβ from the other hemibrain, sequential 
fractionation was performed with SDS (2%) and formic acid (FA, 70%), and Aβ levels 
were measured using the enzyme-linked immunosorbant assay (ELISA). Compared to the 
buffer only control, A, L, and Fon injected mice had an increase in both Aβ40 and Aβ42 
levels in both the SDS and FA fractions (Figure 3.1d). The increase was highest in the 
brains of mice injected with Fon aggregates, followed by Ls and As. Overall, the data 
reveal a 3-4 fold-increase in Aβ40 and Aβ42 in SDS, and a 7-8 fold-increase in FA 
fractions, following neonatal administration of Fon and L seeds. Together, the data 
suggest that LFAOs are capable of inducing propagation and widespread deposition of 
Aβ aggregates, and specifically induce CAA in TgCRND8 mice brains. 
 36 
 
Figure 3.1 LFAOs selectively induce widespread amyloid deposition and CAA in 
TgCRND8 mice 
(a) Newborn CRND8 mice were injected with 4 μL Aβ Fon, Ls, As (10 μM), or PBS buffer (control) in the cerebral ventricles. Three 
months post-injection, brains were extracted and one hemibrain fixed and stained with anti-Aβ antibody. Amyloid staining of plaques 
and CAA in the representative paraffin sections is shown in the cortex, meningeal vessels and choroid plexus, and in the hippocampus 
of injected mice. Scale bars are 500 μm in cortex and CAA images, while 250 μm in hippocampus images. (b) Quantification of Aβ 
positive immunostaining. Data represent mean ± sem. n = 6–10/group. ***p < 0.01, unpaired two-tailed t test. (c) Quantification of 
CAA in blood vessels throughout the brain, done in a blind manner. Data represents mean ± sem. n = 6–10/group. ***p < 0.01, 
unpaired two-tailed t test. (d) Biochemical analyses of sequentially extracted Aβ42 and Aβ40 levels by end-specific sandwich ELISA 
in SDS soluble and formic acid extractable insoluble fractions. Data represents mean ± sem. n = 6–10/group. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001, 2-way Anova with Tukey’s multiple comparison test. 
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3.3 Seeding of monomer with 12-24mer LFAOs shows marked deviation from other 
seeding regimes 
After identifying that the propagation of LFAOs within mice brains specifically 
lead to CAA (Figure 3.1), the kinetics of L seeding in vitro was investigated to obtain 
mechanistic insights into LFAO propagation. Seeding was initiated on As (50 μM) with 
Ls (10 μM) and the kinetics of aggregation was monitored by the widely utilized 
fluorescence dye, thioflavin-T (ThT; Figure 3.2). Control reactions of As only (unseeded, 
Un) and As seeded with Fon aggregates (10 μM) were also monitored. Sigmoidal growth 
with a lag time of 8 days was observed in the Un sample (Figure 3.2a, ☐), which is 
expected for Aβ monomer in the absence of seeds. By seeding As with Fon aggregates 
(sFib), the lag time was abolished, resulting in immediate growth towards fibrils (Figure 
3.2a, ). Seeding As with Ls (sLFAO) displayed a biphasic growth curve (Figure 3.2a, 
). Over the first 6 days of incubation, sLFAO samples displayed a slow incremental 
increase in growth followed by a rapid growth phase and saturation thereafter. This 
growth curve suggests that L and Fon seeding pathways differ, which warrants further 
investigation.  
Samples were analyzed by PAGE at the saturation point of growth (14 days, 
Figure 3.2b-c). Under denaturing conditions (SDS-PAGE), HMW fibrillar aggregates 
were observed in all samples (Figure 3.2b, lanes 1-3). In addition, sLFAO samples 
contained a significant amount of soluble oligomers (Figure 3.2b, lane 3), which are 
likely dissociated species generated during electrophoresis under denaturing conditions. 
To decipher if this is the case, samples were also analyzed in non-denaturing (native 
PAGE) conditions without SDS treatment (Figure 3.2c). A, Fon, and L were used as 
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controls (Figure 3.2c, lanes 4-6). The immunoblots showed that Fon seeds migrated the 
least, followed by Ls and As. Analyzing the samples after 14 days of incubation revealed 
HMW aggregates in all samples (Figure 3.2c, lanes 7-9). However, a second species with 
a lower mass/charge (m/z) was observed in the sLFAO sample (lane 9), confirming the 
presence of soluble species even after the saturation point of aggregation. This oligomeric 
species migrated with a higher m/z as compared to the L control, indicating it may be a 
larger species.  
 
Figure 3.2 12-24mer LFAOs seed fibrils in a unique fashion with distinct biophysical 
characteristics  
(a) ThT fluorescence aggregation kinetics of A (50 μM) in the absence of a seed (Un, ) or seeded with 10 μM Ls (sLFAO, ) or Fon 
seeds (sFib, ). (b) Denaturing (SDS) PAGE of Un (1), sFib (2), and sLFAO (3) at 14 days of incubation. The single and double 
arrows represent Aβ 12mer (56 kDa) and 24mer (110 kDa), respectively. (c) Non-denaturing (native) PAGE of A (4), Fon (5), and L 
(6) along with Un (7), sFib (8), and sLFAO (9). The lower, middle, and upper dashed lines represent native migration of LFAO 
12mer, 24mer, and HMW oligomeric species, respectively. 540 ng was loaded into each well for all samples. (d) Percentage of 
solubility, as determined by centrifugation and ThT fluorescence, at 28 days of incubation (14 days at 25 °C + 14 days at 4 °C). (e-f) 
Quantitative SEC of sLFAO (e) and sFib (f) at 4, 5, 6, and 7 days of incubation, respectively. The arrows represent the trends from 4-7 
days. (g-h) Representative AFM images of fractions 19 (g) and 16 (h) from sLFAO at 7 days of incubation. Scale bar represents 1 μm. 
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To investigate this further, the solubility of aggregates after four weeks of growth 
(14 days at 25 °C + 14 days at 4 °C) was analyzed by ThT fluorescence after 
centrifugation at 18,000g for 20 min (Figure 3.2d). The solubility (%) was determined by 
normalizing the ThT fluorescence in the supernatant against that of the total sample 
before centrifugation. This indicated that Un and sFib samples have 30-40% of soluble 
aggregates, while sLFAO samples have ~65%, in agreement with electrophoresis 
experiments (Figure 3.2b-c). In order to learn more about the size of species populated 
during the sLFAO reaction, SEC was utilized (Figure 3.2e). Aliquots of seeding reactions 
from Figure 3.2a were taken at 4, 5, 6, and 7 days of incubation and fractionated on a 
Superdex-75 column. Initially, the sLFAO (Figure 3.2e) sample fractionated into two 
peaks corresponding to soluble oligomers (fraction 18) and unreacted monomers (fraction 
25). As the seeding reaction proceeded, the monomer and oligomer peaks decreased as a 
third peak, eluting at fraction 16, emerged. This indicates that a transient oligomeric 
species is populated during the initial slow growth phase of biphasic sLFAO aggregation. 
This was not the case with sFib samples (Figure 3.2f), revealing a distinct seeding 
property of LFAOs. AFM was utilized to investigate the morphology of the transiently 
formed oligomeric species (Figure 3.2g), which revealed punctate dots similar to what 
has been reported previously for Ls106 as well as larger, elongated aggregates. These 
elongated species may be the transient species formed during the initial slow growth 
phase of sLFAO aggregation, and warrant further investigation. Finally, AFM was used 
to confirm that the peak near the void volume (fraction 16) contained larger fibrils of 1-2 
μm in length (Figure 3.2h). Together, these data reveal that Ls seed monomers toward 
fibrils via a pathway differing from that of Fon seeding.  
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3.4 sLFAO fibril morphology reveals mechanistic insights into propagation 
In order to examine if sLFAO aggregation leads to fibrils with a distinct 
morphology, samples were analyzed using AFM 10 days after initiating seeding reactions 
(Figure 3.3). AFM images of the Un (Figure 3.3a-c) and sFib (Figure 3.3d-f) reactions 
revealed long fibrils with average cross-sectional heights of 6.3 and 6.1 nm, respectively. 
Analysis along the surface of the aggregates (Figure 3.3k-l) showed a smooth 
morphology void of any distinctive patterns. While a relatively similar average cross-
sectional height of 5.8 nm was observed for sLFAO aggregates (Figure 3.3g-i), further 
analysis indicated a unique repeating morphology along the fibril axis (Figure 3.3m). To 
ascertain if such a morphology could be due to the association of LFAO seeds, AFM of 
Os was performed, which revealed punctate dots with an average height of 6.3 nm 
(Figure 3.4j and n). Overlaying the cross-sectional analysis of Os (dashed line) with the 
sLFAO surface analysis (solid line) showcased that each peak of the repeating pattern 
represents an O (12mer) assembly (Figure 3.3m). After analyzing 30 fibril segments from 
multiple images and fields, this morphology was observed in 67% of sLFAO aggregates, 
while in only 23% of Un and sFib aggregates, respectively (Figure 3.3o). Overall, this 
reveals that LFAOs faithfully propagate to form morphologically-unique fibrils 
containing repeating oligomer assemblies. 
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Figure 3.3 sLFAO fibril morphology reveals mechanistic insight  
(a-j) AFM images of Un (a-c), sFib (d-f), and sLFAO (g-i) aggregates at 10 days of incubation, along with Os (j). Scale bars represent 
200 nm. (k-n) Surface morphology analysis of Un (k), sFib (l), sLFAO (m, solid), and Os (n), as indicated by the black arrows. The 
dashed lines in panel (m) represent data from Os in panel (n). (o) Statistical analysis of AFM images.  
 
3.5  Sonication of sLFAO fibrils generates smaller propagating units 
Considering sLFAO fibrils are made up of O units leads to question if LFAO 
seeds can be regenerated upon the breakdown of fibril samples, as has been previously 
observed for PrP.126 Therefore, sonication was utilized to generate fragments of Un, sFib, 
and sLFAO aggregates, which were then purified via SEC and analyzed using 
immunoblotting (Figure 3.4). Sonication of all samples resulted in predominantly two 
peaks when fractionated on a Superdex-75 column (Figure 3.4a-c), one peak eluting near 
the void volume (V0, fractions 17-19) corresponding to oligomeric species, and another at 
a more inclusive volume (fractions 24-27) corresponding to monomeric species. The 
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oligomeric peak for sonicated samples (solid lines) eluted at a more inclusive volume as 
compared to the samples before sonication (dashed lines), indicating a reduction in the 
size of aggregates upon sonication. Fractionation after the sonication of Un samples 
(Figure 3.4a) revealed a smaller oligomeric peak (and corresponding larger monomeric 
peak) as compared to sFib (Figure 3.4b) and sLFAO (Figure 3.4c) samples. This suggests 
that sonication of Un not only generates oligomeric seeds, but also some monomers. 
Samples before and after sonication, as well as SEC fractions of sonicated samples, were 
then analyzed by immunoblotting under both denaturing (Figure 3.4d) and non-
denaturing (Figure 3.4e) conditions. This showed the presence of ~160 kDa oligomers in 
fraction 18 from Un and sFib samples, as well as some fibrils and monomers. However, 
fraction 18 of sLFAO samples showed a differing banding pattern. In the denaturing 
immunoblot, oligomers corresponding to Ls were observed, which could be due to 
sonication or also due to dissociation in the presence of 1% SDS. In the non-denaturing 
immunoblot (Figure 3.4e), fraction 18 of sLFAO samples (lane 6) migrated with a larger 
m/z as compared to Ls (lane 3), indicating SDS to be the cause of the 12-24mers 
observed in the denaturing gel. This suggests that sonication and isolation of sLFAO 
samples (herein referred to as iLFAOs) produces fragments larger than Ls. 
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Figure 3.4 Sonication of sLFAO fibrils generates smaller propagating units  
(a-c) SEC chromatograms before (dashed) and after (solid) sonication of Un, sFib, and sLFAO samples, respectively. The downward 
arrow represents the void volume (V0) of the column. Inset) Chromatograms showing the full elution profile including monomers. (d) 
Immunoblot of aggregates under denaturing conditions before (B) and after (A) sonication as well as fractions (17–19) from SEC after 
sonication. Single and double arrows represent Aβ 12 and 24mer, respectively. (e) Non-denaturing (native) immunoblot of A (1), Fon 
(2), and L (3), along with Un (4), sFib (5), and sLFAO (6) samples before and after sonication, as well as fraction 18 from 
fractionation after sonication. The lower, middle, and upper dashed lines represent the native migration of LFAO 12mer, 24mer, and 
HMW oligomeric species. 540 ng was loaded into each well for all samples.  
 
3.6 ‘Repeat morphology’ is also observed in iLFAO fragments 
AFM and dynamic light scattering (DLS) were used to further characterize 
iLFAO fragments generated by sonication of sLFAO fibrils (Figure 3.5). AFM images of 
sonicated and isolated Un (Figure 3.5a-b) and sFib (Figure 3.5c-d) fragments (termed iUn 
and iFib, respectively), revealed a uniform size ~120 nm in length. Furthermore, the 
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morphology along the surface of these samples (Figure 3.5g-h) appeared to be smooth, as 
observed prior. While iLFAO fragments were of a similar length (Figure 3.5e-f), the 
morphology again showed a unique repeating pattern (Figure 3.5i) in which the peaks 
seem to correlate with the height of individual O assemblies (dashed line). Analyzing 
multiple images revealed a consistent pattern of 4-6 peaks in iLFAO fragments, 
suggesting them to be 4-6 times larger than the dodecameric Os. This was further 
corroborated using DLS, which yielded a diameter of ~38 nm for iLFAOs (Figure 3.5j), 
roughly 4 times larger than the previously reported size of Os.106 Like observed in the 
length analysis from AFM images, DLS revealed all fragments to be of a similar size, 
suggesting that sonication parameters (power level, sonication time, number of cycles, 
etc.) may play a role in the size of fragments produced.  
The varying LFAO species (Ls, iLFAOs, and sLFAOs) were further characterized 
by ANS binding and CD spectroscopy (Figure 3.6). ANS binding (Figure 3.6a) revealed 
that Ls () contain more solvent exposed hydrophobic regions, as evidenced by 
increased binding. No significant difference between iLFAO () and sLFAO () ANS 
binding was observed. Using far-UV CD, it was shown that all samples have a β-sheet 
secondary structure (minima at 217 nm), of which the extent was less in Ls (Figure 3.6b).  
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Figure 3.5 Repeat morphology is retained within iLFAO fragments  
(a-f) AFM images of sonicated and isolated (fraction 18) Un (iUn, a-b), sFib (iFib, c-d), and sLFAO (iLFAO, e-f). Inset) AFM images 
used for surface analysis. Scale bars for (a, c, and e) represent 1 μm, while (b, d, and f) and insets represent 200 nm. (g-i) Surface 
morphology analysis, as indicated by black arrows. The dashed line in panel (i) represents O analysis from Figure 3.3n. (j) DLS of 
fractions 18 of iUn, iFib, and iLFAO samples. **represents p < 0.05.  
 
 
Figure 3.6 Biophysical comparison of Ls, iLFAOs and sLFAOs 
(a) ANS (100 μM) fluorescence scans of 10 μM sLFAO (), iLFAO (), and L (), respectively. Samples were equilibrated 1 min 
before measuring fluorescence using an excitation of 388 nm and scanning emission between 405 and 650 nm. (b) CD spectra for 10 
μM sLFAO (dashed), iLFAO (solid), and L (dotted). The vertical line indicates 217 nm. 
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3.7 Conclusions 
The data presented here, together with the data presented in Chapter II and 
previously by Kumar et al.,105, 106 reveals a holistic picture of Aβ dodecamer (LFAO) 
propagation, which proceeds in three distinct macroscopic phases (Scheme 3.1). In the 
initial replication phase, Os (12mers) undergo self-propagative replication in the presence 
of As, as reported previously.105 Upon reaching a threshold concentration, Os associate to 
form Ls as indicted in Chapter II. As shown here, Ls then seed toward morphologically-
unique Fs, but do so in a biphasic manner suggesting the formation of at least one 
intermediate. Using sonication and AFM, it was revealed that smaller fragments of Fs, 
made up of 4-6 O units, can be generated and isolated. These novel LFAO intermediate 
species, which we are denoting as Ps, are the rate-limiting species formed during the 
second phase of LFAO propagation. Upon formation of Ps, Fs are rapidly formed 
(propagation phase) via reactions which are not yet defined. Interestingly, inoculation of 
Ls in transgenic mice specifically induced CAA, supporting the idea that the faithful 
propagation of conformationally-unique Aβ oligomers to polymorphic fibrils contributes 
to the observed phenotypic diversity in AD. Overall, this reveals molecular-level insight 
into the propagation mechanism of one such conformational Aβ oligomer strain. 
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Scheme 3.1 A schematic representation of the mechanism of LFAO propagation
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CHAPTER IV – DETAILS OF LFAO PROPAGATION PROBED BY MASS ACTION 
KINETICS 
4.1 Introduction 
In the previous chapter, the faithful propagation of Os to morphologically-unique 
fibrils containing repeating oligomer units was established. It was revealed that O 
propagation occurs in three macroscopic phases: replication, an intermediate phase 
involving P generation, and propagation (Figure 4.1a). However, the microscopic 
reactions defining the macroscopic phases have yet to be established. In this chapter, the 
microscopic reactions were investigated by dissecting the macroscopic phases and 
evaluating the kinetics of each reaction individually. The rate constants derived from 
these in vitro reactions were used to build an ensemble kinetic simulation (EKS) model. 
Collectively, this has yielded novel insight into the reaction mechanism of LFAO-strain 
propagation, which is discussed below. The results presented herein were originally 
disseminated by Dean et al. in the Biophysical Journal,127 and are reproduced here. 
 
4.2 LFAO propagation at varying seed concentrations 
As described in Chapter II, LFAOs display concentration-dependent dynamics 
between O and L assemblies. In Chapter III, the biphasic behavior involved in the 
propagation of Ls toward Fs was described (Figure 4.1b, ). To investigate if 
conformational dynamics plays a role in the biphasic seeding behavior, seeding reactions 
were initiated at 0.1 () and 1 () μM LFAOs (Figure 4.1b), where the O/L fraction is 
increased (more Os, less Ls). As expected, seeding of O/Ls resulted in a decreased lag 
time as compared to the unseeded A control (Figure 4.1b, ). However, the biphasic 
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curve observed in 10 μM O/L seeding was not observed at 10- and 100-fold lower 
concentrations (Figure 4.1b). This may be due to an increase in the competing on-
pathway aggregation (self-nucleation of As) in low seeding conditions, which is 
elaborated below. 
 
 
Figure 4.1 O/L propagation at varying seed concentrations 
(a) A schematic representation of the reactions and rate constants considered in LFAO strain-specific propagation. These include 
monomer elongation (ME), oligomer elongation (OE), and oligomer association (OA) reactions, respectively. Adapted from 124 with 
permission. (b) A (50 μM) seeded with 0.1 (), 1 (), or 10 () μM O/Ls, respectively. The unseeded A control is represented by 
().  
 
4.3 Monomer elongation predominates in the replication and intermediate phases 
The microscopic reactions considered in the replication and intermediate phases, 
along with the corresponding rate constants obtained, are listed in Table 4.1. The 
elongation of Os by As (monomer elongation, ME) was considered in the replication 
phase, while both ME and oligomer association (OA) were considered in the intermediate 
phase involving the generation of Ps. 
To investigate the kinetics of these reactions, the initial rate method and ThT 
fluorescence were employed, which have both been previously used to analyze other 
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amyloid proteins.128 To investigate the rate of ME, the reactions were initiated at varying 
concentrations of As (1 (), 10 (), 25 (), and 50 () μM) with a constant seed 
concentration (O/Ls) of 5 μM (Figure 4.2a). The data revealed that increasing the 
concentration of A increased the rates of the reactions (Figure 4.2a). Initial rates of each 
reaction were obtained from the slope of the linear fit of the initial time points (t0-t300 s; 
Table 4.2). Plotting the initial rates against the initial A concentration revealed a linear 
correlation (Figure 4.2d, ), suggesting the reaction to be first order with respect to A. 
Additionally, the slope of this plot represented the rate constant (k’O/LME), which was 0.43 
x 10-3 s-1. To determine if O/L conformational dynamics played a role in reaction kinetics, 
similar experiments were performed at 1 () and 10 () μM seed concentrations, which 
yielded k’O/LME values of 0.018 x 10-3 s-1 and 0.42 x 10-3 s-1, respectively (Figure 4.2d). 
Plotting the rate constant values against the initial O/L concentration revealed a deviation 
from linearity at 1 μM (Figure 4.2b), supporting the model (Figure 4.1a) that Os do not 
seed toward P formation, but rather undergo replication to form Ls.  
 
Table 4.1 A comprehensive list of reactions and their corresponding rate constants 
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To determine the reaction order with respect to the O/L concentration, varying 
amounts of O/Ls (0.1 (), 1 (), 5 (), 7.5 (), and 10 () μM) were seeded with a 
constant concentration (50 μM) of As (Figure 4.2c). Similar to what was observed prior, 
increasing the seed concentration lead to increased rates. A linear relationship was found 
by plotting the initial rates against the initial O/L concentration (Figure 4.2d, ), 
suggesting a first order reaction with respect to the seed. Together with the previous data, 
this reveals an overall second order reaction for ME in the intermediate phase. The rate 
constant for the varying O/L reactions (k’’O/LME) was found to be 5.48 x 10-3 s-1, which is 
~13 fold higher than k’O/LME. This suggests that the amount of seeds, not As, drives the 
reaction toward the formation of Ps.  
 
Table 4.2 Experimentally determined initial rates of ME, OA, and OE reactions detailed 
in this work 
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Figure 4.2 Kinetics of replication and intermediate phases  
(a) ThT fluorescence of 1 (), 10 (), 25 (), and 50 () μM A seeded with O/L (5 μM), respectively. (b) The rate constant (k’O/LME) 
for reactions at 1, 5, and 10 μM O/L, respectively. (c) ThT fluorescence of A (50 μM) seeded with 0.1 (), 1 (), 5 (), 7.5 (), and 
10 () μM O/L, respectively. (d) Initial rates, as calculated by the slope of the linear line from the first 300 s of the reactions in panels 
(a) and (c). (e) ThT fluorescence of 1 () and 10 () μM O/L, respectively. Inset) Initial rates from the first 150 s of the reactions. 
The symbol * represents p<0.005 from statistical t test. 
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The conversion of Ls to Ps in the intermediate phase may also occur through the 
association (OA) of O/Ls in the absence of As. To investigate this, kinetics were 
monitored at 1 () and 10 () μM O/Ls upon the addition of 100 mM NaCl (Figure 
4.2e), which has been shown previously to promote lateral association of Aβ 
protofibrils.35, 129 The initial rates of these reactions indicated that, compared to 1 μM, 
association is enhanced at 10 μM where LFAOs primarily exist as Ls (Table 4.2). 
Comparing the rate of OA against that of ME reactions at similar concentrations revealed 
that ME is preferred over OA (Table 4.2), suggesting that the conversion of Os to Ps 
primarily occurs through ME. 
 
4.4 Oligomer elongation predominates in the propagation phase 
The conversion of Ps to Fs in the propagation phase may occur through ME, P 
association (PA), or a third pathway where Ps serve as a template for O/Ls to bind and 
elongate (oligomer elongation, OE). Investigating these reactions in vitro is challenging 
due to the transient nature of P formation. However, as shown in Chapter III,124 short 
fragments of 4-6 O units can be generated and isolated via sonication of Fs. Therefore, 
this method was employed to generate apparent P units, which were then investigated for 
ME, PA, and OE kinetics (Table 4.1). ME reactions were investigated by seeding 1 (), 
10 (), 25 (), 50 (), and 70 () μM As with a constant concentration (5 μM) of Ps 
(Figure 4.3a). As observed with previous reactions, increasing concentrations of As 
resulted in an increase in the rate of the reaction. However, plotting the initial rates 
against the initial A concentration revealed a Michaelis-Menten type plot (Figure 4.3c). 
At low A concentrations, the rate increased linearly with the A concentration, suggesting 
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a first order reaction. However, at increased A concentrations there was a plateau of the 
rate, suggesting a zero order reaction. Overall, this suggests that there are a limited 
number of seeding ends in Ps, which upon saturation by As results in no further increase 
in the rate of the reaction. The initial first order reaction (1, 10, and 25 μM points) were 
used to determine the rate constant (k’PME), which was 2.6 x 10-3 s-1.  
To investigate whether the saturation of the initial rate at increased A 
concentrations is due to the limited number of binding sites on P, reactions were initiated 
with increasing amounts of Ps (0.1 (), 1 (), 5 (), 7.5 (), and 10 () μM) and a 
constant amount (50 μM) of As (Figure 4.3b). We hypothesized that increasing the 
amount of Ps will likewise increase the number of seeding ends, which would not result 
in a plateau of the initial rate. Plotting the initial rates against the initial P concentration 
(Figure 4.3c) resulted in a linear relationship, confirming this hypothesis. The rate 
constant (k’’PME) for this reaction, 24.4 x 10-3 s-1, was ~10 fold higher than k’PME, 
suggesting that the amount of Ps in the system, not As, drives the reaction forward.  
To investigate the lateral association of Ps, experiments were initiated in the 
presence of 100 mM NaCl (Figure 4.3d), similar to what was described above. PA was 
monitored at 1 () and 10 () μM, which as expected yielded an increase in the rate of 
association at the increased concentration. Comparing these initial rates with those of the 
ME reactions at the same P concentrations (Table 4.2) reveled a 5-6 fold-increase of ME 
over PA (Table 4.2), similar to what was observed for O/Ls. To investigate the kinetics of 
OE in the propagation phase, Ps (5 μM) were mixed with 1, (), 3 (), 5 (), or 7 () 
μM O/Ls, respectively (Figure 4.4a). Plotting the initial rates against the initial O/L 
concentration revealed a linear, first order, correlation (Figure 4.4b) with a rate constant 
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(k’POE) of 7.4 x 10-3 s-1.  Comparing this to k’PME indicated a 3-fold higher rate of OE to 
ME, suggesting that Ps primarily form Fs by addition of O/Ls, not As. 
 
 
Figure 4.3 ME and PA kinetics in the propagation phase  
(a) ThT fluorescence of 1 (), 10 (), 25 (), 50 (), and 70 () μM A seeded with P (5 μM), respectively. (b) ThT fluorescence of 
A (50 μM) seeded with 0.1 (), 1 (), 5 (), 7.5 (), and 10 () μM P, respectively. (c) Initial rates, as calculated by the slope of 
the linear line from the first 300 s of the reactions in panels (a) and (b). (d) ThT fluorescence of 1 () and 10 () μM P, respectively. 
Inset) Initial rates from the first 150 s of the reactions. The symbol ** represents p<0.001 from statistical t test. 
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Figure 4.4 OE kinetics in the propagation phase 
(a) ThT fluorescence of 1 (), 3 (), 5 (), and 7 () μM O/Ls seeded with Ps (5 μM), respectively. (b) Initial rates, as calculated 
by the slope of the linear line from the first 150 s of the reactions in panel (a). 
 
4.5 Temporal simulation of LFAO propagation 
As shown above, Ls grow toward Fs in a biphasic manner, suggesting the 
formation of a larger intermediate, termed Ps. While in vitro experiments in Chapter III 
have revealed that sonication of Fs generates LFAO fragments 4-6 times greater than O 
12mers, similar sized fragments were also observed in other samples. In order to bring 
clarity to this issue and unambiguously determine the size of Ps, in silico numerical 
simulation analysis was performed using ordinary differential equations (ODEs) to build 
an EKS model to define LFAO propagation. Similar methods have been employed 
previously to yield novel insight into Aβ aggregation.35, 130 However, attempts to fit the 
biphasic 10 μM seeding reaction using previously defined platforms, such as the widely 
utilized ‘AmyloFit’,131 were unsuccessful (Figure 4.5a-c), suggesting the need to develop 
a model specific for LFAO propagation. 
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Figure 4.5 Global fits from the ‘AmyloFit’ platform 
 (a-c) The 0.1 (a), 1.0 (b), and 10 μM (c) seeding reactions fit using the ‘multi-step secondary nucleation dominated’ model in the 
AmyloFit 131 software. 
 
To develop such a model, the results from the in vitro kinetic experiments were 
used in the ODE simulated rate constants (e.g., kO/LME > kO/LA and kPOE > kPME). The 
complete list of parameters and the equations considered can be found in Chapter VIII. 
Overall, the model considered that the replication and intermediate phases occur through 
ME, and not by OE, as supported by experimental observations. Also, simulations were 
initiated at varying ratios of Os and Ls based on the seeding concentration (0.1, 1, or 10 
μM) and the Kd for O/L dynamics (0.1 μM, see Chapter II). The size of P was floated 
from 36-120 A units (O3 – O10) and evaluated for the best fit to determine the P size. 
Reasonable fits were obtained for P sizes of A48 – A84 (O4 – O7; Figure 4.6b), which is in 
good agreement with the sonication and AFM data in Chapter III. While ME reactions 
were exclusively considered in the replication and intermediate phases, all reactions (ME, 
PA, and OE) were considered in the propagation phase. Overall, this EKS model shows 
good agreement with the experimental LFAO seeding reactions (Figure 4.6a), which can 
be defined by ODEs with a single set of global rate constants (Figure 4.6c). Additionally, 
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this model incorporates the contribution from the competing on-pathway reaction (Fon), 
which increased with decreasing seeding concentrations (Figure 4.6d). 
 
 
Figure 4.6 EKS Model of LFAO propagation  
(a) Aggregation profiles from the EKS model (solid lines) with the experimental unseeded () and 0.1 (), 1 (), and 10 () μM 
O/L seeded reactions, respectively. P size = 48mer. (b) RMSE and least R2 values at each respective gateway (P) size. (c) Estimated 
rate constants for P = 48mer. (d) Fon/F for 0.1, 1.0, and 10 μM seeding reactions. 
 
 
Figure 4.7 Flux analysis from the EKS model 
The concentration (μM) flux of A, O, L, P, F, and Fon, Aβ species during the 0.1 (a), 1 (b), and 10 (c) μM O/L seeding reactions for the 
EKS model described in the text. 
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The EKS model is also able to quantitatively simulate the temporal evolution of 
the various species (As, Os, Ls, Ps, Fs, and Fon) during the seeding reaction (Figure 4.7). 
These quantitative concentration values were compared to that of experimental values 
calculated from SEC data at 4, 5, 6, and 7 days of 10 μM LFAO seeding (Figure 4.8a). 
The SEC peaks were considered to be either fibrils (F + Fon, ), oligomers (Os + Ls + 
Ps, ), or monomers (As, ), and the fraction of each species was plotted against time 
(Figure 4.8b). Comparing these results with that from the simulation revealed a good 
agreement between the EKS model and experimental data, further validating the model. 
 
 
Figure 4.8 EKS and experimental quantitative analysis 
(a) SEC fractionation of 10 μM LFAO seeding at 4, 5, 6, and 7 days of incubation, respectively. The dashed arrows represent the 
trends from days 4-7. Reproduced from Chapter III. Fractions 16-17 () represent fibrils, fractions 17-20 () represent oligomers, 
while fractions 23-27 () represent monomers. (b) Quantification of the fraction of fibrils, oligomers, and monomers from 
experimental (symbols) or simulated (P=48mer, lines) data. (c) RMSE values for panel (b). 
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4.6 Conclusions 
This chapter presents mass action-based kinetic insight into the LFAO 
propagation mechanism. The overall seeded aggregation was dissected and individual 
reactions such as ME, OE, and OA were investigated for each phase of propagation. The 
data suggest that the conversion of Ls to Ps primarily occurs through ME reactions, and 
that the amount of O/Ls drive the reaction to completion. It was similarly observed that 
the conversion of Ps to Fs is driven by the amount of Ps, however the primary 
mechanism for conversion is by OE, not ME. The kinetic insights from these reactions 
were used to build an EKS model, which was validated quantitatively by comparing the 
flux of Aβ species from experimental results. Overall, this has yielded unique and novel 
insights into the molecular events defining the strain-specific propagation of Aβ 
dodecamers in vitro, which involved a three-step seeded process. Such a seeding 
mechanism has not been reported before, making this potentially significant in 
understanding strain propagation, which is essential in order to develop strategies that 
target and inhibit the process in the AD brain. This work provides a platform for 
characterizing Aβ strains by their rates of propagation, which may be used to better 
establish and characterize distinct phenotypes among AD patients.
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CHAPTER V – LFAO CROSS-PROPAGATION 
5.1 Introduction 
The previous chapters have established that LFAOs are an Aβ oligomer strain 
capable of undergoing both replication and propagation with Aβ42 WT monomers. As 
discussed in Chapter I, CAA is a cerebrovascular pathology that emanates from 
deposition of Aβ, particularly mutant isoforms, within the cerebral vessels of the brain.11-
13 A high incidence of CAA exists among AD patients,12, 13 which leads to questions if an 
interplay exists between WT and mutant isoforms of Aβ, leading to the co-existence of 
both pathologies. Additionally, the interplay of various Aβ isoforms may lead to novel 
hybrid oligomer strains with distinct biophysical properties and pathological 
consequences. Therefore, in this chapter the cross-propagation of Aβ42 WT LFAOs 
(herein referred to as LFAOs) with other Aβ isoforms was explored to yield insight into 
this process. 
 
5.2 LFAO cross-propagation with WT and Arctic-Aβ40 
Initially, the cross-propagation of LFAOs with Aβ40 WT monomers was 
explored, as Aβ40 is the predominant isoform of Aβ found in the brain and thus may play 
a significant role in AD pathology. To do this, LFAOs (5 μM) were seeded upon Aβ40 
WT monomer (30 μM) and allowed to interact for 72 h at 25 ºC in quiescent conditions 
(seeded; Figure 5.1a). Aβ40 WT monomer in the absence of a seed (C) and the LFAO 
seed alone (seed) served as controls. Compared to the seed alone, the immunoblot 
showed an amplification of ~56 kDa Os in the seeded sample (Figure 5.1a). The 
monomer control sample had a single band at 4.5 kDa corresponding to As, indicating 
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that no oligomers were formed by the self-nucleation of Aβ40 WT in these reaction 
conditions. To confirm that the amplification of the 56 kDa oligomer was due to 
incorporation of Aβ40 WT, similar reactions were initiated with N-terminally labeled 
fluorescein isothiocyanate Aβ40 (FITC-Aβ40 WT). It was hypothesized that 
amplification can occur either by the self-association of Aβ40 WT on the LFAO 
template, or by insertion within the LFAO assembly (Figure 5.1b). In either condition, 
the presence of FITC in the isolated oligomer would suggest the incorporation of Aβ40 
WT in the cross-propagated oligomer. SEC fractionation of the LFAO seeded reaction 
with FITC-Aβ40 WT (Figure 5.1c) yielded a 1.5-fold amplification over the seed alone. 
Immunoblotting analysis confirmed the isolation of 56 kDa oligomers in fractions 17 and 
18 (Figure 5.1c, inset). Analyzing the fractions for FITC fluorescence revealed the 
presence of FITC-Aβ40 WT in fractions 16-18, as evident by the emission maxima at 525 
nm upon excitation at 490 nm (Figure 5.1d). The maximum FITC fluorescence was found 
in fraction 17, which was in agreement with the band intensities in the immunoblot 
(Figure 5.1c). Overall, this suggests that LFAOs can cross-propagate with Aβ40 WT 
monomers, leading to an amplification of novel hybrid oligomers containing both Aβ40 
and Aβ42 WT isoforms.  
To investigate whether this can occur with Aβ40 E22G (Arctic-Aβ40) monomers, 
similar reactions were initiated by seeding Arctic-Aβ40 monomers (25 μM) with LFAOs 
(2 μM, Figure 5.1e). The immunoblot revealed the amplification of 56 kDa Os in the 
seeded sample, although the fold-increase from the seed alone seemed diminished as 
compared to cross-propagation with Aβ40 WT. Regardless, this unveils an additional 
mechanism of LFAO cross-propagation leading to hybrid oligomer formation. 
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Figure 5.1 Cross-propagation of LFAOs with WT and Arctic Aβ40 monomer  
(a) Immunoblot of LFAOs (1.5 μM) alone (seed) or after incubation with Aβ40 WT monomer (30 μM) for 72 h at 25 °C (seeded). 
Aβ40 WT monomer in the absence of a seed served as a control (C). (b) A schematic representation of FITC-labeled reactions in 
panels (c) and (d). (c) SEC fractionation of LFAO seeds (2.5 μM) alone or seeded with 50 μM Aβ40 WT monomer (20% FITC-
labeled). Inset, an immunoblot of the seeded reaction before SEC (B), and of fractions 16-18, respectively. (d) FITC fluorescence of 
fractions 16-18 of SEC from panel (c). (e) Immunoblotting analysis of LFAOs (2 μM) alone (seed) or after incubation with Arctic-
Aβ40 monomer (25 μM) for 72 h at 25 °C (seeded). Arctic-Aβ40 monomer in the absence of a seed served as a control (C). 
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5.3 LFAO cross-propagation with Arctic-Aβ42 
As shown in Figure 5.1e, cross-propagation of LFAOs with Arctic-Aβ40 
produced hybrid oligomers roughly 56 kDa in size. To investigate if the Arctic-Aβ42 
isoform showed similar trends, LFAOs (5 μM) were seeded upon Arctic-Aβ42 monomer 
(50 μM) and allowed to incubate at 25 ºC for 24 h. The immunoblot (Figure 5.2a) 
revealed the formation of a disperse cross-propagated oligomer containing predominantly 
two size distributions at 56 (single arrow) and 110 (double arrow) kDa. This is analogous 
to what was observed when seeding LFAOs with Aβ42 WT monomers, as shown in 
Chapter II. To confirm that the cross-propagation was due to incorporation of Arctic-Aβ, 
FITC-labeled Arctic-Aβ42 monomers were used (Figure 5.2b). SEC fractionation yielded 
a two-fold increase in the cross-propagated species eluting at fraction 17 in the seeded 
sample, and the immunoblot confirmed the oligomers to be 56-110 kDa in size (Figure 
5.2c). The presence of FITC in the fractions (Figure 5.2d) confirmed that the oligomer 
amplification was due to incorporation of Arctic-Aβ42. The highest FITC fluorescence 
was found in fraction 17, followed by fraction 18 and 16, which corroborates with the 
immunoblotting data. Overall, this reveals an additional mode of cross-propagation 
among LFAOs leading to the formation of hybrid oligomers. 
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Figure 5.2 Cross-propagation of LFAOs with Arctic-Aβ42 Monomer  
(a) An immunoblot of LFAOs (5 μM) alone (seed) or after incubation with Arctic-Aβ42 monomer (50 μM) for 24 h at 25 °C (seeded). 
Arctic-Aβ42 monomer in the absence of a seed served as a control (C). (b) A schematic representation of FITC-labeled reactions in 
panels (c) and (d). (c) SEC profiles of LFAO seeds (2 μM) alone or seeded with 40 μM FITC Arctic-Aβ42 monomer (100% FITC-
labeled). Inset, an immunoblot of the seeded reaction before SEC (B), and of fractions 16-18. (d) FITC fluorescence of fractions 16-18 
of SEC from panel (c). 
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5.4 Reverse cross-propagation of Arctic-Aβ42 oligomers with Aβ42 WT monomer 
To explore the possibility of mutant Aβ oligomers cross-propagating with WT Aβ 
monomer (reverse cross-propagation), conditions for generating and isolating Arctic-
Aβ42 oligomers were optimized. As discussed in Chapter I, Kumar et al. have shown 
previously that incubation of C12:0 NEFAs near or above their CMC promotes oligomer 
formation with Aβ42 WT monomers.104 Therefore, Arctic-Aβ42 monomer (50 μM) was 
allowed to aggregate in the presence of C12:0 NEFA micelles (15 mM) for 24 h at 37 ºC 
in quiescent conditions. Analyzing the samples by SDS-PAGE with immunoblotting 
showed the formation of 30-40 kDa oligomers (Figure 5.3a, lane B), which was not 
observed in the control reaction without C12:0 (lane C). Fractionation of the oligomers 
using a Superdex-75 column (Figure 5.3b) resulted in three predominant peaks; fibrils 
(fraction 15), oligomers (fraction 18), and monomers (fraction 26), which is in agreement 
with the immunoblotting data (Figure 5.3, lane B). Furthermore, the immunoblot 
confirmed the presence of 30-40 kDa (~8-9mer) oligomers in fractions 17 and 18 (Figure 
5.3a, lanes 17 and 18).  
To explore the propensity of Arctic oligomers to reverse cross-propagate, Aβ42 
WT monomers (25 μM) were seeded with Arctic-Aβ42 oligomers (1 μM) and allowed to 
incubate at 25 ºC for 72 h in quiescent conditions. Immunoblots of reactions revealed the 
formation of a larger, 40-80 kDa oligomer in the seeded sample (Figure 5.3c). As 
expected, the control reaction of unseeded Aβ42 WT monomer (lane C) did not show 
formation of any oligomers within these reaction conditions. Fractionation of the seed 
and seeded samples revealed a 4.4 fold-increase of reverse cross-propagated oligomers in 
the seeded sample (Figure 5.3d). Overall, these results showcase that Arctic-Aβ42 
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oligomers can be generated in interfacial reaction conditions similar to what has been 
reported previously for Aβ42 WT LFAOs;104 and the reverse cross-propagation of Arctic 
oligomers with WT monomers suggests additional modes of hybrid oligomer formation 
within the complex Aβ interactome. 
 
 
Figure 5.3 Reverse Cross-propagation of Arctic-Aβ42 Oligomers with Aβ42 WT 
Monomer 
(a-b) A representative immunoblot (a) and SEC profile (b) of Arctic-Aβ42 oligomers formed upon incubation of monomer (50 μM) 
with 15 mM C12:0 fatty acid at 37 °C for 24 h. Lane B represents the sample before SEC, while 17 and 18 represent fractions from 
SEC in panel (b). Monomer in the absence of C12:0 served as a control (C). (c-d) A representative immunoblot (c) and SEC profile 
(d) of Arctic-Aβ42 oligomers (1 μM) alone (seed) or after incubation with Aβ42 WT monomer (25 μM) for 72 h at 25 °C (seeded). 
Aβ42 WT monomer in the absence of a seed served as a control (C). 
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5.5 Conclusions  
In this chapter, the formation of hybrid oligomers derived from the interplay of 
WT and Arctic (E22G) Aβ isoforms has been demonstrated. LFAOs of Aβ42 WT were 
able to cross-propagate with Aβ40 WT, Arctic-Aβ40, and Arctic-Aβ42 monomers to 
form hybrid oligomers of varying sizes. Furthermore, reverse cross-propagation of Arctic 
oligomers with Aβ42 WT monomers lead to hybrid oligomers unique from that of 
LFAO/Arctic hybrid oligomers. These preliminary results shed light into the potential 
complex interplay of Aβ species within the AD brain, and reveal the seemingly unlimited 
possible reactions present within the Aβ interactome. Further investigation into the 
structure-phenotype relationship of hybrid oligomers is necessary to delineate their 
physiochemical and neuropathological consequences, as discussed in Chapter VII. 
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CHAPTER VI – PHOSPHATIDYLGLYCEROL- AND GANGLIOSIDE-DERIVED 
OLIGOMERS 
6.1 Introduction 
The majority of the work presented thus far has shown that LFAOs propagate 
toward fibrils in a biphasic mechanism resulting in the selective induction of CAA in 
transgenic mice. As hypothesized in Chapter I, a family of Aβ oligomer strains may be 
generated using different micelle- and liposome-forming lipids. This hypothesis will be 
explored in this chapter by evaluating the ability of the anionic phospholipid, 
phosphatidylglycerol (PG), to induce Aβ oligomerization. Oligomer formation in the 
presence of the ganglioside GM1 will also be investigated, as it has been widely 
implicated in AD pathology (discussed in Chapter I). The results presented here 
showcase that both micellar and liposomal lipids generated by PG and GM1 modulate Aβ 
aggregation pathways toward Aβ oligomer formation. 
 
6.2 Micelle-derived oligomer strains 
6.2.1 Generation and isolation of Aβ oligomers in the presence of anionic micelles 
As shown previously by Rangachari et al., as well as others, the anionic surfactant 
SDS is capable of inducing the generation of stable, off-pathway Aβ oligomers.102, 103 
More recently, Kumar et al. have shown that anionic NEFAs also promote off-pathway 
Aβ oligomer formation under a narrow regime of NEFA concentrations.104 Since both 
SDS and NEFAs are micelle-forming surfactants, it warrants investigation into whether 
anionic phospholipids, which are primary components of cellular membranes, could also 
behave similarly in inducing the formation of off-pathway oligomers. Lyso-PG (LPG) is 
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similar to both SDS and NEFAs in that it contains a single acyl chain and forms micelles 
as opposed to bilayer-containing liposomes. Aβ oligomer formation was investigated in 
the presence of LPG micelles containing saturated acyl chains of 14 (C14:0 LPG), 16 
(C16:0 LPG), or 18 (C18:0 LPG) carbons in length (Figure 6.1). Aβ monomer (50-60 
μM) was added to C14:0, 16:0, or 18:0 LPG micelles buffered in 20 mM Tris (pH 8.0) 
containing 50 mM NaCl and allowed to incubate at 37 °C in quiescent conditions for 48 
h. While the final concentration of LPG in each reaction varied based on the lipid species 
(see Table 8.1 in Chapter VIII), the concentration was kept at least two-fold above the 
reported CMC to ensure the lipids were in a micellar form.132 After incubation, the 
reactions were electrophoresed and visualized via immunoblotting, which revealed the 
formation of soluble, 30-60 kDa oligomers in the presence of LPG micelles (Figure 6.1a). 
The control reaction in the absence of LPG (Figure 6.1a, lane C) contained HMW fibrils, 
a broad HMW oligomer, and monomers, respectively. This suggests that the 30-60 kDa 
oligomers generated in the presence of LPG micelles was due to the presence of the 
micelles. Furthermore, the size of the LPG-derived oligomers (LPGOs) seemed to 
correlate with the acyl chain length of the micelle, with longer carbon chains inducing 
larger oligomers (Figure 6.1a).  
Fractionation of LPGO samples on a Superdex-75 column (Figure 6.1b-d) 
revealed predominantly three Aβ species, mainly monomers, oligomers, and fibrils, 
which corroborates with the immunoblotting data. Similar fractionation of the control 
reaction (Figure 6.1b-d, dashed lines) showed only fibrils and oligomers, further 
indicating that the LPGOs are formed due to the presence of the micelles, not the reaction 
conditions. Immunoblotting of the fractionated LPGOs (Figure 6.1f) revealed that the 
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least inclusive peak (fraction 17) contained fibrils, as expected. The more inclusive peak 
eluting at fractions 18-20 contained the soluble oligomers generated in the presence of 
the LPG micelles, while the fractions at the most included volume (fraction 25) 
represented monomeric Aβ (Figure 6.1f). The predominant species generated in the 
presence of C14:0 and C16:0 LPG micelles were the soluble oligomers (C14 LPGOs and 
C16 LPGOs, respectively). However, this was not the case for Aβ in the presence of 
C18:0 micelles, which contained more fibrils (fraction 17) than oligomers (Figure 6.1b-
d). This was clear from the presence of fibril bands in fractions 18-20 of the immunoblot 
(Figure 6.1f, C18 LPGO), which was reflected in the poor resolution of the two species 
during SEC (Figure 6.1d). Nevertheless, the collective data indicate that LPG micelles 
promote the formation of Aβ oligomers which, in the case of C14 and C16 LPGOs, can be 
isolated via SEC. 
The anionic glycosphingolipid, GM1, is also a micelle forming lipid species with 
a CMC in the low micromolar range.133, 134 As discussed in Chapter 1, several reports 
indicate GM1 as a significant contributor to Aβ aggregation in the AD brain.86, 87, 95, 96 To 
investigate the connection between GM1 and Aβ further, Aβ monomer (50-60 μM) was 
incubated in the presence of GM1 micelles buffered in 20 mM Tris (pH 8.0) containing 
50 mM NaCl and the reaction was allowed to incubate at 37 °C in quiescent conditions 
for 48 h. Immunoblotting analysis of the reaction (Figure 6.1e, GM1) show the formation 
of an Aβ oligomer with a bimodal molecular-weight distribution centered at ~40 and ~56 
kDa, respectively. Unlike LPGO reactions, no HMW fibrils were observed in the 
immunoblot of GM1 derived oligomers (GM1Os). This was confirmed by SEC 
fractionation (Figure 6.1e), which yielded just two peaks corresponding to the oligomers 
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(Figure 6.1f, fractions 18-20) and monomers (fraction 25), respectively. The absence of 
HMW fibrils was further established by immunoblotting analysis of fraction 17, in which 
no fibril bands were observed (Figure 6.1f). Overall, this suggests that GM1 micelles 
catalyze the formation of distinct Aβ oligomers without detectable fibril formation. 
 
 
Figure 6.1 Generation and isolation of micelle-derived oligomers  
(a) A representative immunoblot of samples before fractionation. The amount of Aβ loaded into each well was kept constant at 1 μg. 
(b-e) SEC of Aβ (50 μM) incubated alone (dashed) or with C14:0 LPG (b), C16:0 LPG (c), C18:0 (d), or GM1 (e) micelles (solid) 
after 48 h of incubation at 37 °C in quiescent conditions. (f) Immunoblotting analysis of fractions 17-20 after fractionation as shown in 
(b-e). The volume of each fraction loaded onto the gel was kept constant at 15 μL. 
 
6.2.2 Biophysical characterization of LPGOs and GM1Os reveals similarities 
To characterize the size and structure of micelle-derived oligomers, LPGO and 
GM1O samples were analyzed by DLS, CD, and FTIR spectroscopy (Figure 6.2). DLS 
size analysis of C14 and C16 LPGO samples before SEC isolation (Figure 6.2a-b) revealed 
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a significant degree of polydispersity present, with ~10 nm diameter species as well as 
larger species ranging from 0.5-5 μm observed. Fractionation of C14 and C16 LPGOs via 
SEC eliminated the larger aggregates, indicating the oligomers to be ~10 nm in diameter 
(Figure 6.2e-f). The C18 LPGO sample prior to SEC isolation contained ~60 nm and ~2 
μm sized aggregates (Figure 6.2c). Attempts to collect DLS spectra of the isolated C18 
LPGO were unsuccessful due to poor yields, as well as poor resolution of fibril and 
oligomer peaks in SEC, as shown above. Unlike LPG-containing samples, GM1Os prior 
and after SEC isolation had similar DLS spectra containing a single peak at ~10 nm 
(Figure 6.2d and g). This further supports that fibril formation is minimal in the presence 
of GM1, and that the oligomers observed could be formed along an alternative, off-
pathway. Overall, the data suggest that C14 and C16 LPGOs, as well as GM1Os, have a 
similar hydrodynamic diameter of 10 nm, which is consistent with the SEC and 
immunoblot data above indicating all oligomers have roughly similar sizes. This is also 
consistent with the size of LFAOs, which has been previously reported to be ~10 nm in 
diameter by Kumar et al.106 
To investigate the structural conformation of LPGOs and GM1Os, CD and FTIR 
were employed (Figure 6.2h-j). Prior to SEC fractionation, a similar CD spectra 
containing a single minima at 217 nm was observed for all samples (Figure 6.1h), 
indicating all aggregates to have β-sheet secondary structure in the presence of micelles. 
Similar spectra were obtained upon isolation (Figure 6.1i), with the exception of C18 
LPGOs, which could not be collected due to poor yield of the oligomeric species. 
However, increased signal intensity was observed for GM1Os (Figure 6.2i), which may 
be due to association of the lipid in the SEC-fractionated oligomer. This possibility was 
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explored and is elaborated in detail below. Regardless, this reveals that LPG and GM1 
micelles promote the formation of β-sheet rich oligomers.  
 
 
Figure 6.2 Biophysical characterization of LPGOs and GM1Os  
(a-d) DLS spectra of Aβ monomer (50-60 μM) in the presence of C14:0 LPG (a), C16:0 LPG (b), C18:0 LPG (c), and GM1 (d) after 
48 h of incubation at 37 °C. (e-g) DLS spectra of isolated C14 (e) and C16 (f) LPGOs, as well as GM1Os (g). (h-i) CD spectra of 
micelle-derived oligomers prior to (h) and after (i) SEC isolation. (j) FTIR of micelle-derived oligomers after isolation (solid lines), as 
well as purified Fon (dashed) and LFAO (dotted) samples. A total of 64 accumulations were collected by scanning 4,000 – 650 cm
-1 at 
a resolution of 4 cm-1. DLS and CD spectra were collected as described in Chapter VIII. 
 
To ascertain the type of the β-sheets (parallel or anti-parallel), FTIR was 
employed (Figure 6.2j).  As initially described in Chapter II, FTIR is able to differentiate 
parallel and anti-parallel β-sheets based on their respective amide stretching 
frequencies.112 FTIR spectra of Fon aggregates (dashed line) and LFAOs (dotted line) 
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were collected as controls (Figure 6.2j), which both gave the expected absorbance 
maxima at 1625 cm-1 indicative of parallel β-sheets. Similar results were obtained for C14 
and C16 LPGOs, as well as GM1Os. In all cases, the presence of anti-parallel β-sheets at 
1690 cm-1 was not observed, suggesting that both LPGOs and GM1Os form parallel β-
sheets. While this is contradictory to recent reports that Aβ oligomers are anti-parallel in 
nature,115-117 it does bring into focus a unifying characteristic among surfactant-derived 
oligomers. 
 
6.2.3 Fractionated GM1-derived oligomers (GM1Os) are not free of GM1, unlike 
LPGOs 
The increased CD signal intensity of fractionated GM1Os, as well as the lack of 
fibril formation observed, may suggest association of GM1 with the oligomer. To 
investigate this possibility, electrospray ionization mass spectrometry (ESI-MS) in 
negative ion mode was utilized (Figure 6.3). Initially, controls of C14:0 LPG, C16:0 
LPG, and GM1 in the absence of Aβ were collected (Figure 6.3a-c), which revealed the 
presence of the [M - 1H]-1 ion for both C14:0 and C16:0 LPGs at 455 and 483 m/z, 
respectively (Figure 6.3a-b). In the case of GM1, multiple signals were observed (Figure 
6.3c) corresponding to the varying sphingosine (denoted ‘d’) and acyl moieties present. 
This primarily included the 1545 ([(d18:1, C18:0) – 1H]-1) and 1573 ([(d20:1, C18:0) – 
1H]-1) m/z ions, which have been observed previously.135-137 Also observed were the 
1612 and 1680 m/z ions, which were unassigned derivatives of GM1, consistent with the 
manufactures warning of multiple GM1 isoforms present in the product. 
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Figure 6.3 ESI-MS of LPGOs and GM1Os  
(a-h) ESI-MS of 10 μM C14:0 LPG (a), C16:0 LPG (b), GM1 (c), Aβ monomer (d), LFAOs (e), C14 (f) and C16 (g) LPGOs, as well as 
GM1Os (h), respectively. Spectra were collected as described in Chapter VIII. 
 
Control Aβ reactions of monomer or LFAO were also examined in negative ion 
mode, which yielded a 1503 m/z signal corresponding to the [M - 3H]-3 Aβ ion (Figure 
6.3d-e). This was also observed in the isolated C14 and C16 LPGO samples, respectively 
(Figure 6.3f-g). Moreover, the C14:0 LPG (455 m/z) and C16:0 LPG (483 m/z) ions were 
absent from the isolated C14 and C16 LPGOs, respectively. This suggests that the two 
species (lipid and Aβ oligomer) are separated upon fractionation in the Superdex-75 
column. However, this was not observed with the isolated GM1O sample (Figure 6.3h), 
in which only ions corresponding to GM1 were present. This suggests that GM1Os are 
tightly bound to GM1 and elute as a co-complex, and the two do not separate during SEC 
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fractionation. This is unlike LPGs, which are able to dissociate from the oligomer 
(LPGO) upon fractionation, similar to what has been reported by Kumar et al. for 
LFAOs.106 In the case of GM1Os, this may explain why fibril formation is not observed 
upon incubation of Aβ monomer with GM1, as well as be reason for the increased 
intensity of the CD signal in GM1Os. 
 
6.2.4 Micelle-derived oligomers seed Aβ fibril formation 
One important question to address is whether LPGOs and GM1Os are capable of 
acting as seeds for Aβ monomer elongation and fibril formation. To investigate this, 
reactions were initiated by seeding Aβ monomer (25 μM) with 3 μM of either C14 LPGO 
(), C16 LPGO (), or GM1O () seeds, respectively (Figure 6.4a). Aβ in the absence 
of seeds served as a control (, Figure 6.4a). Reactions were buffered in 20 mM Tris (pH 
8.0) with 50 mM NaCl and were maintained in quiescent conditions at 37 °C for 7 days. 
ThT measurements were taken periodically to monitor aggregate growth, which in the 
case of the control reaction (, Figure 6.3a) revealed a typical sigmoidal growth curve 
with a lag time of ~24 h. Seeding Aβ monomer with micelle-derived oligomers resulted 
in a decreased lag time, as evidenced by the incremental increase in ThT fluorescence 
beginning at 18 h. While this does suggest that both LPGOs and GM1Os are capable of 
seeding Aβ monomer toward fibril deposition, it remains to be understood if they lead to 
distinct fibril polymorphs. Also, it is important to bear in mind that since GM1 is present 
in the fractionated GM1O (as shown above), it is therefore also present in the seeding 
reaction. Thus, the observed fibril formation in the GM1O seeding reaction seems 
contradictory to what was observed above upon incubation of GM1 micelles with Aβ 
 78 
monomer. However, it is important to remember that the concentration of GM1 in the 
SEC fractionated GM1O would be significantly decreased as compared to the GM1 
concentration prior to SEC (75 μM), which is due to the dilution that occurs upon passage 
through the Superdex-75 column. Therefore, GM1 at low concentrations may promote 
fibril formation as oppose trapping Aβ monomers in an oligomeric state.  
 
 
Figure 6.4 Micelle-derived oligomers seed Aβ fibril formation  
(a) Aβ monomer (25 μM) alone () or seeded with 3 μM C14 LPGOs (), C16 LPGOs (), or GM1Os (). (b) The percent solubility 
after 7 days of incubation, as determined by ThT fluorescence and centrifugation (18000g for 20 min). 
 
To shed insight into whether the seeded reactions lead to unique fibril 
polymorphs, the percentage of soluble Aβ at the end of the reactions were monitored by 
ThT fluorescence and centrifugation (Figure 6.4b). As shown in Chapter III for LFAO 
propagation, LFAO-seeded fibrils displayed an increased solubility as compared to Fon 
aggregates. The same analysis was therefore performed for LPGO- and GM1O-seeded 
fibrils, which in the case of the control reaction revealed only ~25% of soluble Aβ 
remaining at the end of the reaction. This was increased to ~40% in the case of LPGO- 
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and GM1O-seeded fibrils, which is consistent with what has been observed previously in 
Chapter III for LFAO-seeded fibrils. While this does not reveal a faithful reproduction of 
the oligomer assembly within the fibril structure, it does suggest the possibility of 
polymorphic fibril structures from LPGO- and GM1O-seeding reactions. 
 
6.3 Anionic liposomes accelerate Aβ aggregation 
The results presented above showcase that micelles of anionic LPG and GM1 are 
capable of inducing the formation of Aβ oligomers with unique biophysical signatures 
and seeding behavior. However, it remains to be understood if liposomal systems are 
similarly able to give rise to distinct Aβ oligomer conformers. Therefore, this was 
investigated using the anionic phospholipid, 1,2-dimyristoyl-sn-glycero-3-phospho-(1’-
rac-glycerol) (DMPG), which contains two saturated acyl chains of 14 carbons (C14:0) 
each (Figure 6.5). Small unilamellar vesicles (SUVs) were prepared in 20 mM Tris (pH 
8.0) buffer by extrusion through a 50 nm Whatman® nuclepore polycarbonate 
membrane, as described in Chapter VIII. Upon extrusion, the SUV size was confirmed by 
DLS, which revealed the successful formation of uniform liposomes having a 
hydrodynamic diameter of ~50 nm (Figure 6.5a). 
To investigate the effect of DMPG SUVs on Aβ aggregation, Aβ monomer (25 
μM) was incubated alone (C) or with increasing concentrations of SUVs from 12.5 
(1:0.5), 25 (1:1), 50 (1:2), 250 (1:10) or 500 (1:20) μM, respectively. Samples were 
buffered in 20 mM Tris (pH 8.0) with 50 mM NaCl and 10 μM ThT and prepared in 96 
well microplates. Reactions were kept at 37 °C inside of a plate reader and aggregate 
growth was monitored by ThT fluorescence every 15 min for 8 h (Figure 6.5b). The Aβ 
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control reaction in the absence of SUVs displayed typical sigmoidal growth kinetics with 
a lag time of ~45 min (Figure 6.5b). Incubation of Aβ monomer with a sub-stoichiometric 
concentration of SUVs (1:0.5, Figure 6.5b) did not result in an observable change in the 
lag time or the final ThT intensity in the saturation phase, which can be used as a rough 
indicator of fibril polymorphs as shown by Spirig et al.74 For samples incubated with a 
1:1 and 1:2 ratio of Aβ:SUVs, a decrease in the lag time and increase in the ThT plateau 
intensity was observed, although the two reactions were indistinguishable from each 
other (Figure 6.5b). A concentration dependent decrease in the lag time was observed for 
the 1:10 and 1:20 reactions, however the ThT plateau intensity did not vary between the 
two reactions (Figure 6.5b). Overall, this reveals that stoichiometric and super-
stoichiometric concentrations of DMPG SUVs increase the rate of Aβ aggregation. 
Moreover, based on ThT plateau intensities of the fibrils, low ratios (1:1 and 1:2) and 
high ratios (1:10 and 1:20) of Aβ:SUVs seem to form fibrils along varying pathways, 
potentially leading to varying fibril polymorphs. However, it remains to be investigated if 
DMPG SUVs promote the formation of Aβ oligomers, or simply accelerate the formation 
of Aβ fibrils. Therefore, further experiments should be done to bring clarity in this 
regard. 
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Figure 6.5 DMPG SUVs accelerate Aβ aggregation  
(a) DLS spectra of DMPG SUVs. (b) ThT fluorescence kinetics of Aβ alone (25 Cor in the presence of 12.5 (1:0.5), 25 (1:1), 
50 (1:2), 250 (1:10), or 500 (1:20)  DMPG SUVs. Inset) An expanded view of the first 2 h of the reaction. The trend line 
represents increasing ratios of Aβ:SUVs.  
 
6.4 Conclusions 
The results presented above reveal that anionic surfactants promote the formation 
of Aβ oligomers along distinct pathways, supporting the hypothesis that varying lipid 
environments are a governing factor in the generation of conformeric oligomer strains. 
Anionic micelles, composed of either LPG or GM1 lipids, promoted the formation of 30-
60 kDa soluble Aβ oligomers, similar to what has been reported in the presence of SDS 
as well as NEFA micelles.102-104 Interestingly, increasing the chain length of LPG 
micelles from C16:0 to C18:0 promoted fibril formation, suggesting that both lipid 
composition (in this example, charge) and size (or surface area) may factor into how 
lipids modulate Aβ aggregation pathways. This is supported by the fact that anionic 
liposomal SUVs, which are much larger than LPG micelles, accelerated Aβ aggregation 
toward fibril formation, as evidenced by ThT fluorescence. No fibrils were observed 
upon incubation of Aβ monomer with GM1 micelles, suggesting that the unique surface 
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created by the oligosaccharide moiety traps Aβ in an oligomeric state. Das et al. have 
reported similar observations with synthetic GM1 glycopolymer mimics, which revealed 
the selective induction of Aβ oligomers by glycopolymers containing purely glucose 
pendant groups.138  
GM1Os were also unique in that they did not dissociate from the lipid upon 
fractionation, which is consistent with earlier reports of a tightly-bound Aβ:GM1 species 
isolated from postmortem AD brains.86, 87 However, LPGOs could be isolated from the 
LPG micelle and remained as a stable oligomeric species, which is similar to what Kumar 
et al. have reported for fatty acid-derived LFAOs.106 Investigation into the conformation 
of the micellar oligomers by CD and FTIR revealed they are composed of parallel β-
sheets, identical to what was reported in Chapter II for LFAOs. This commonality among 
oligomers derived from anionic micelles suggests they may be part of a larger family (or 
class) of oligomer strains, which is discussed in detail below (Chapter VII). While further 
work is needed to unambiguously define LPGOs and GM1Os as oligomer strains (as 
elaborated in Chapter VII), this work does reveal that distinct lipid environments can in 
fact modulate Aβ aggregation pathways towards the formation of conformationally-
unique Aβ oligomers. 
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CHAPTER VII – CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Propagation of Aβ oligomer strains: LFAOs as model oligomers 
 Chapters II-IV showcase a mechanistic insight into the self-propagation of an Aβ 
oligomer strain (LFAOs), which seem to selectively induce CAA in transgenic mice 
brains. We now know that the mechanism of LFAO propagation involves three distinct 
phases of replication, generation of an intermediate, P, followed by propagation to 
mature Fs. At low concentrations, Os undergo replication, resulting in a 5-7 fold-increase 
of oligomers (Chapter II). While this may seem modest, in a physiological scenario, even 
small amplifications from a numerically large number of LFAO-like replicating oligomer 
seeds could result in widespread dissemination of such oligomers with significant 
consequences. The fact that LFAOs induce maximum toxicity at low concentrations (10 
nM), where they primarily exist as Os (Chapter II), further provides credence to this 
hypothesis. Furthermore, the increase in the local concentration of oligomers results in 
the conformational conversion from Os to Ls in vitro (Kd = 0.1 M, Chapter II). This 
dynamic also manifest in the kinetics of ME reactions, whereby a significant deviation 
from the linear rate constant occurs at low seeding concentrations (Chapter IV), 
suggesting that Os do not directly seed toward Ps. It is interesting that the conformational 
conversion from Os to Ls is the ‘switch’ which initiates propagation towards Fs. While L 
formation seems to be the rate-initiating factor for propagation, they do not directly seed 
Fs, but rather undergo elongation by As to form a key intermediate, Ps, which are 4-7 
times larger than the initial dodecamer seed (Chapters III and IV). This type of 
mechanism seems to parallel recent reports of multiple nucleation events in amyloid 
aggregation,139-141 although it should be borne in mind the investigations presented here 
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are of seeded aggregation, where nucleation events are thought to be significantly 
suppressed or eliminated altogether. As evidenced in this work, this may not necessarily 
be the case and may vary based on the size and conformation (i.e. strain) of the 
propagating seed. In summary, this work presents a case wherein a self-propagating 
oligomer strain constitutes the foundation of a phenotypic variant in AD (CAA), 
cementing the idea that polymorphic Aβ oligomers govern phenotypic diversity in AD. 
 
7.2 Future directions 
7.2.1 Molecular details of the LFAO structure 
High concentrations of LFAOs show parallel β-sheets by FTIR, which is in 
conflict with some recent reports that predict anti-parallel β-sheets for amyloid 
oligomers.115-117, 142 This suggests that LFAOs have a structure distinct from other 
reported oligomers, which could explain their ability to replicate. Furthermore, other 
micelle-derived oligomers (LPGOs and GM1Os) have similar parallel β-sheet amide 
stretching FTIR spectra, suggesting it may be a unifying characteristic of interfacially-
derived oligomers. To probe this further, the structure of LFAOs should be investigated 
at the atomic level using techniques such as solid and solution state nuclear magnetic 
resonance (NMR) spectroscopy, isotope-edited FTIR spectroscopy, molecular dynamics 
(MD) simulations, among others. Kotler et al. have shown that high-resolution structural 
elucidation of Aβ40 oligomer conformations can be obtained using 1H-1H dipolar 
couplings from NMR.143 Similar experiments, as well as solid-state NMR measurements, 
have been initiated in collaboration with Dr. Ramamoorthy at The University of 
Michigan, which will yield more details on the molecular organization of LFAOs. The 
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distance constraints derived from the NMR experiments, along with other size and 
conformational insights from the biophysical experiments presented here, will be 
considered in MD simulations conducted by Dr. Hansmann at The University of 
Oklahoma, which has been described previously for Aβ oligomers.144 Collectively, this 
will yield an atomic resolution structure of LFAOs. Using this platform, similar NMR 
experiments and MD simulations will be done using LPGOs and GM1Os, and the 
respective structures will be compared to that of other oligomers reported in the literature 
to identify structural characteristics unique to interfacially-derived oligomers. The 
structural details of the oligomers will also allow for the rational design and development 
of inhibitors (small molecules, peptides, etc.) of LFAO replication, which is the primary 
and most toxic phase of LFAO propagation in vitro. 
 
7.2.2 Cross-propagation of heterogeneous Aβ isoforms leads to hybrid oligomers 
A recent review by Condello and Stohr introduced the hypothesis that the 
observed structural heterogeneity and phenotypic diversity in AD arises from a complex 
interplay of Aβ isoforms within what they term the ‘Aβ interactome’.71 However, a 
mechanistic understanding of such a phenomenon, specifically oligomer-to-oligomer 
cross-propagation of Aβ isoforms, is lacking. Chapter V of this document describes that 
seeding LFAOs with heterogeneous Aβ monomers results in the generation of hybrid 
oligomer species containing multiple isoforms of Aβ. Furthermore, Arctic-Aβ42 
oligomers are able to seed WT monomers, which reveals that cross-propagation is 
bidirectional and need not originate from a specific Aβ isoform.  
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While this unambiguously confirms cross-propagation of Aβ isoforms in vitro, the 
physiological consequences of such mechanisms remain unknown. This is currently 
being explored and will be disseminated at a later date, but includes in vitro cell toxicity 
assays to address i) the overall toxicity of hybrid aggregates vs. their homogeneous seeds 
and ii) the specific mechanisms/avenues of toxicity (activation of inflammatory 
pathways, apoptosis, necrosis, etc). Additionally, inoculation of hybrid aggregates into 
transgenic mice have been initiated to explore differences in the neuropathological 
localization/spreading. Overall, this will yield much needed insights and provide a 
platform for further delineation of the complex mechanisms within the Aβ interactome. 
 
7.2.3 A new perspective in classifying oligomer strains 
While the interplay of Aβ isoforms may contribute to strain generation through 
the formation of hybrid oligomers (as described in 7.2.2), we believe that other, 
heterotypic interactions also influence this process. This is showcased in Chapter VI, 
which reveals that anionic lipid micelles act as catalysts to generate soluble oligomers of 
Aβ in vitro. Biophysical characterization of these LPGOs and GM1Os has revealed 
similarities to LFAOs, such as their size (~10 nm hydrodynamic diameter) and secondary 
structure (parallel β-sheets). The latter suggests that the macroscopic structure of 
oligomers derived from anionic micelles are shared, and leads to question if they also 
share physiochemical properties. Seeding reactions seem to suggest they do, revealing 
LPGOs and GM1Os seed fibrils with nearly identical ThT kinetic profiles. Also, the fact 
that LPGO-, GM1O-, and even LFAO-derived fibrils have increased solubility as 
compared to Fon aggregates further supports this notion. This leads to hypothesize that 
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while oligomers may have varying atomic structures (thus can be categorized as 
conformational strains), they may also have shared traits (such as those listed above) 
which allow them to be grouped into certain families or classes. However, this should be 
read with caution as the mechanism of LPGO and GM1O propagation has yet to be 
explored, the atomic structures of these oligomers are currently unknown, and the 
phenotypic manifestation(s) of LPGOs and GM1Os in vivo remain to be understood. 
Furthermore, the cell-to-cell transmission of LFAOs via neuronal trafficking mechanisms 
has yet to be investigated, which is a well-defined feature of PrP strains145-147 and is 
considered a canonical characteristic of a bona fide strain.67 Thus, this leads to ambiguity 
in classifying these oligomers as distinct strains, and these points should be investigated 
before making definitive conclusions. Regardless, it is clear from the data presented that 
other anionic micellar lipid systems are capable of catalyzing Aβ oligomer formation, 
yielding insight into how oligomer strains may be populated within the complex cerebral 
microenvironment of the AD brain. 
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CHAPTER VIII – MATERIALS AND EXPERIMENTAL PROCEDURES 
8.1 Materials  
Lyophilized stocks of synthetic Aβ42 WT, Aβ40 WT, and Arctic-Aβ42 peptides 
were procured from the Mayo Clinic (Rochester, MN), while FITC-Aβ40 WT and FITC-
Arctic-Aβ42 were obtained from the Yale School of Medicine (New Haven, CT). Dr. 
Yona Levites at the University of Florida (Gainesville, FL) kindly provided the 
monoclonal Ab5 antibody that was used. SEC columns (Superdex-75 HR 10/30) were 
purchased from GE Life Sciences (Marlborough, MA). The equipment and materials for 
gel electrophoresis and immunoblotting, including SuperSignalTM West Pico 
Chemiluminescent Substrate, were purchased from either Thermo Fisher Scientific, Inc. 
(Waltham, MA) or Bio-Rad Laboratories, Inc. (Hercules, CA). LPG (C14:0, C16:0, and 
C18:0), DMPG, and GM1 lipids were procured from Avanti Polar Lipids, Inc. (Alabaster, 
AL); while C12:0 NEFA was procured from NuCheck Prep, Inc. (Elysian, MN). 
Purchased from Sigma-Aldrich Corp. (St. Louis, MO) were Tris base, Tris hydrochloride, 
DCVJ, BSA, SDS, Triton X-100, as well as all cell culture media. Other essential 
chemicals, reagents, and consumables were purchased from either VWR, Inc. (Radnor, 
PA) or Thermo Fisher Scientific, Inc. (Waltham, MA).  
 
8.2 General methods 
8.2.1 Purification of Aβ monomers 
To purify synthetic Aβ monomer in all isoforms, 0.5-2 mg of lyophilized peptide 
was dissolved in 490 μL of nanopure H2O (npH2O) and allowed to stand at 25 °C for 0.5-
1 h. Ten minutes before loading onto a Superdex-75 HR 10/30 SEC column attached 
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either to an AKTA FPLC system (GE Healthcare, Buckinghamshire) or a BioLogic 
DuoFlowTM system (BioRad), NaOH was added to a final concentration of 10 mM. 
Monomer was then purified by loading the sample onto a pre-equilibrated (20 mM Tris, 
pH 8.0) column and fractionating at a flow rate of 0.5 mL/min at 25 °C. Fractions of 500 
μL were collected, and monomeric Aβ was found to elute in the ~23-27th fraction. A Cary 
50 UV-Vis spectrometer (Agilent Technologies, Inc.; Santa Clara, CA) was used to 
determine the molar concentration of Aβ in each fraction, which for non-FITC labeled 
samples was done using Beer-Lambert’s law ( = 1450 cm-1 M-1 at 276 nm). In the case 
of FITC labeled samples, protein concentrations were determined by the following 
equation: 
𝐴276𝑛𝑚 − (𝐴494𝑛𝑚 𝑥 0.3)
1450
 
Where A276nm represents the absorbance from the Tyr residue in Aβ, A494nm represents the 
absorbance from FITC, 0.3 represents the correction factor (provided by Thermo Fisher 
Scientific ‘Tech Tip #31’) and 1450 represents the extinction () coefficient of Aβ.  
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was used to 
confirm the purity and integrity of the peptide. The purified monomers were stored at 4 
°C and used to initiate experiments within 48 h of purification. 
 
8.2.2 Purification of Aβ oligomers 
Purification of Aβ oligomers was initiated by incubating freshly purified Aβ 
monomer with the specified lipid species in the conditions listed in Table 8.1.  
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Table 8.1 Conditions for generating Aβ oligomers 
 
All samples were kept at 37 °C in quiescent conditions for 48 h. The samples were then 
purified via SEC, as described above, after first pelleting the insoluble peptide by 
centrifugation at 18000g for 20 min. Fractions of 500 μL were collected, and Aβ 
oligomers were found to be in the 18-20th fraction. The molar concentration was 
determined by UV-Vis spectroscopy, as described above. Samples were either stored at 4 
°C and used for experimentation within 72 h, or lyophilized and kept at -80 °C for 
extended storage prior to experimentation.  
 
8.2.3 Lyophilization and resuspension of Aβ 
For lyophilization, aliquots of either 1 or 5 μg were made and flash-frozen by 
plunging into liquid N2 for 30 s prior to freeze-drying overnight using a FreeZone® 
TriadTM freeze dry system (Labconco Corp.; Kansas City, MO) maintained at 0.420 
mBar. Lyophilized samples were then stored at -80 °C until use. To resuspend the 
lyophilized samples for experimentation, either npH2O or Tris buffer (pH 8.0) was added 
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to reach the desired molar concentration of peptide, and the sample was allowed to stand 
at 4 °C for at least 1 h prior to centrifugation at 18000g for 20 min. The supernatant was 
then carefully removed and used for experiments.  
 
8.2.4 Generation of Aβ fibrils 
Aβ fibrils were generated by either inducing the nucleation of Aβ monomer (Fon) 
or by seeding with O/Ls (Fs). Aβ monomer (100−150 μM) was added to 150 mM NaCl 
and allowed to incubate at 37 °C in quiescent conditions for 4−5 days for Fon generation. 
After incubation, the sample was subjected to centrifugation at 18000g for 20 min before 
carefully discarding the supernatant and resuspending the pellet in fresh 20 mM Tris (pH 
8.0) with 0.01% NaN3. ThT fluorescence and centrifugation were used to determine 
percentage conversion to Aβ fibrils, which was typically 80−90%. Fibrils were stored at 4 
°C and used within 30 days. Generation of Fs was done by seeding Aβ monomer (50 μM) 
with 10 μM of O/Ls in 20 mM Tris (pH 8.0) with 0.01% NaN3. ThT was used to monitor 
the reactions daily for a total of 14 days of quiescent incubation at 25 °C. The samples 
were then subjected to an additional 14 days of quiescent incubation at 4 °C, upon which 
they were stored at 4 °C until sonication to generate fibril fragments called Ps. 
 
8.2.5 Generation of Ps 
To generate Ps, Fs stored in 1.5 mL siliconized tubes were sonicated (on ice) 
using a Misonix (Farmingdale, NY) XL-2000 series unit with a 2.4 mm diameter 
microprobe, kept at a depth of 17 mm inside of the tube. Samples were subjected to 7 
cycles of sonication at 80% power, with each cycle consisting of 5 s of sonication 
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followed by 20 s of rest. The sample was then immediately fractionated using SEC, as 
described above, and the peak near the void volume (fractions 15-18) were collected. The 
concentration of each fraction was determined by UV-Vis spectroscopy, as described 
earlier, and the samples were stored at 4 C to be used within 72 h of purification. 
 
8.2.6 Oligomer seeding reactions 
For O/L replication reactions, Aβ monomer (50 μM) was seeded with varying 
concentrations of O/Ls in 20 mM Tris (pH 8.0) and allowed to react in quiescent 
conditions at 25 °C for 72 h. Qualitative analysis of replication was done by subjecting 
the samples to electrophoresis and immunoblotting. Quantitative analysis was done by 
subjecting the samples to SEC analysis and normalizing chromatograms for the seeded 
reactions against the corresponding chromatograms for the seeds alone, after first 
pelleting the insoluble material by centrifugation at 18000g for 20 min. Due to the 
variability of cross-propagation reaction conditions, they are not listed here. However, 
they are provided for each individual reaction in the figure legends, which can be found 
in Chapter V. For C14 and C16 LPGO, as well as GM1O seeding reactions, Aβ monomer 
(50 μM) was seeded with 3 μM oligomer seeds in 20 mM Tris (pH 8.0) with 50 mM 
NaCl and 0.01% NaN3. The reactions were kept in quiescent conditions at 37 °C and ThT 
fluorescence was monitored for 7 days.  
 
8.2.7 Denaturing and non-denaturing PAGE with immunoblotting 
Samples were diluted into 1X Laemmli loading buffer either with (denaturing) or 
without (non-denaturing) 1% SDS, and loaded, without boiling, onto either 4-12% 
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NuPAGE or 4-20% Bis-Tris BioRad TGX gels. Pre-stained molecular-weight markers 
(Novex Sharp Protein Standard, Life Technologies) were run in parallel for MW 
determination in denaturing PAGE. For immunoblotting, proteins were transferred onto a 
0.2 μm nitrocellulose membrane (BioRad). Following the transfer, the immunoblot was 
boiled for 1 min in a microwave oven in 1X PBS, followed by blocking for 1.5 h at 25 °C 
in 1X PBS containing 5% nonfat dry milk with 1% Tween 20. Blots were then probed 
overnight at 4 °C with a 1:6000 dilution of Ab5 monoclonal antibody, which detects 
amino acids 1–16 of Aβ. Following primary incubation, blots were probed with a 1:6000 
dilution of anti-mouse, horseradish peroxidase-conjugated secondary antibody for 1.5 h at 
25 °C before being imaged using a SuperSignalTM West Pico Chemiluminescent 
Substrate kit (Thermo Fisher Scientific). 
 
8.2.8 DMPG liposome preparation 
DMPG SUVs were prepared by first transferring an aliquot of DMPG (10 
mg/mL) suspended in chloroform:methanol (1:1) into a glass vial, followed by 
evaporating it to dryness using vacuum evaporation. Next, the dry lipid ‘cakes’ were 
resuspended at a final concentration of 1.67 mg/mL in warm (37 °C) 20 mM Tris (pH 
8.0) buffer. The sample was then hydrated for 1-2 h by agitating on an orbital shaker (250 
rpm) kept inside of a 37 °C incubator. Periodically (every 5-10 min), the sample was 
removed and vortexed for 30 s to decrease the time required for hydration. Once 
hydrated, the sample was transferred into a siliconized microcentrifuge tube and 
subjected to 10 freeze/thaw cycles. Each cycle consisted of first plunging the sample into 
liquid N2 for 30 s, followed by a boiling water bath for an additional 30 s. Following the 
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10th freeze/thaw cycle, the sample was extruded by passing it a total of 19 times through a 
50 nm Whatman® NucleporeTM track-etch polycarbonate membrane using an Avanti 
mini-extruder kept on top of a 45 °C heating block. SUVs were then analyzed by DLS to 
confirm their size, followed by determining the concentration using Beer-Lambert’s law 
from the absorbance at 210 nm. The ε coefficient was experimentally determined to be 
69.1 cm-1 M-1 using a standard absorbance curve from known concentrations of LPG. 
SUVs were stored at 4 °C and used for experimentation within 48 h of extrusion. 
 
8.3 Biophysical methods 
8.3.1 ThT fluorescence kinetics 
Excluding section 6.3 of this dissertation, ThT fluorescence measurements were 
collected by monitoring emission at 482 nm while exciting the sample at 452 nm using a 
Cary Eclipse fluorometer (Agilent Technologies, Inc.) in kinetics mode. For ThT 
measurements of extended reactions (>24 h), measurements were collected after a 1 min 
equilibration upon mixing 70 μL of a ThT stock (10 μM) with 5 μL of each respective 
sample. For experiments monitoring the initial reaction kinetics (Chapter IV), ThT (10 
μM) emission was collected every 30 s for 1 h immediately upon mixing samples. 
For section 6.3 of this dissertation, samples were prepared in non-treated, NuncTM 
MicroWellTM microplates (Thermo Fisher Scientific) and ThT measurements were 
collected in a Synergy H1 microplate reader (BioTek Instruments Inc., Winooski, VT) 
operated by Gen5TM version 2.07 software. Top optics position measurements were 
collected every 15 min at 37 °C with excitation and emission wavelengths of 452 and 482 
nm, respectively. The gain was kept constant throughout the measurements at 70 (unit-
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less as defined in the software). Prior to each measurement collection, the microplate was 
orbitally shaken for 1 s at a frequency of 205 cpm. 
 
8.3.2 ANS, DCVJ, and FITC fluorescence 
Using a Cary Eclipse fluorometer (Agilent Technologies, Inc.) in scan mode, 
ANS, DCVJ, or FITC fluorescence were measured. For ANS, fluorescence was measured 
by exciting the sample at 388 nm while scanning emission between 400 and 650 nm upon 
the addition of Aβ (6 μM) and ANS (100 μM). DCVJ fluorescence was collected by 
exciting the sample at 433 nm while scanning emission between 400 and 650 nm upon 
the addition of Aβ (5 μM) and DCVJ (10 μM). In titration experiments, samples were 
diluted to the desired concentration by adding the dilution buffer (100 M ANS in 20 
mM Tris, pH 8.0) directly to the cuvette, followed by a 1 min equilibration before 
measuring fluorescence. The area under the curve was normalized against each respective 
Aβ concentration, and then plotted against the Aβ concentration to give the curves 
represented in Chapter II. The data obtained for LFAO ANS binding were fit to the 
following monomer−dimer model using Origin 8.5 software.  
𝐹 =
2
𝑀
∗ {𝐹0 − (𝐹0 − 𝐹𝑓 ) ∗ (
(4𝑀 +  𝐾𝑑) ± √(4𝑀 +  𝐾𝑑)2 − 16𝑀2 
8
)} 
Here, F is the fraction of dimer (24mer), M is the total Aβ concentration, F0 is the initial 
fluorescence value, Ff is the final fluorescence value, and Kd is the apparent dissociation 
constant. For FITC measurements, cross-propagated oligomer fractions were excited at 
490 nm while scanning the emission spectrum from 510-600 nm. The slit widths were 
kept constant at 10 nm.  
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8.3.3 Fourier transform infrared (FTIR) spectroscopy 
For measurements presented in Chapter II, FTIR was performed in grazing angle 
attenuated total reflectance mode (GATR) using a Nicolet 8700 (Thermo Fisher 
Scientific) instrument equipped with a VariGATRTM accessory (grazing angle 65, 
germanium crystal; Harrick Scientific). For measurements in Chapter VI, a Nicolet 6700 
instrument equipped with a ATR accessory was used. In both cases, Aβ was lyophilized 
using either vacuum evaporation or methods described above prior to collecting spectra. 
Aβ samples were then resuspended in D2O to a final concentration of 1 mM before 
accumulating spectra as described in the text. Spectra were processed by blank 
subtraction (using D2O as the blank) and baseline correction using OriginLab 8.0 
software. 
 
8.3.4 Circular dichroism (CD) spectroscopy 
A Jasco (Easton, MD) J-815 spectropolarimeter was used to collect an average of 
6-16 spectral scans in the far-UV region (260-190 nm) at a rate of 50 nm/min (8 s 
response time, 1 nm bandwidth, 0.1 nm data pitch). Averaged spectra were smoothed 
using the Savitzky-Golay algorithm with a convolution width of 15 using the Jasco 
spectrum analysis program.  
 
8.3.5 Dynamic light scattering (DLS) 
DLS was collected by averaging 12 runs of 10 s each with a pre-equilibration time 
of 30 s using a Zetasizer Nano S instrument (Malvern, Inc., Worcestershire, UK). The 
diameter was determined using the volume (%) function. 
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8.3.6 Electrospray ionization mass spectrometry (ESI-MS) 
All samples were evaporated to dryness using vacuum evaporation followed by 
resuspension at a concentration of 10 μM in a water:acetonitrile:formic acid (1:1:0.2) 
solvent. Samples were analyzed by direct infusion into a FinniganTM LXQTM ion trap 
mass spectrometer (Thermo Fisher Scientific) operated in negative ion mode. Signals 
were accumulated by scanning the spectrum from 150-2,000 m/z for a total of 3 min 
(~800 total scans) at a constant flow rate of 100 μL/min. Other instrument parameters 
were kept as follows: spray voltage (5 kV), capillary temperature (275 °C), capillary 
voltage (-42 V), and automatic gain control (1.5 x 104).  
 
8.3.7 Atomic force microscopy (AFM) 
AFM was conducted by Pradipta K. Das in Dr. Sarah Morgan’s lab at The 
University of Southern Mississippi. Briefly, the mica was cleaved using a razor blade and 
taped to a magnetic sample holder. The mica stub was then covered with 150 μL of 3-
aminopropyltriethoxysilane solution (500 μL of 3-aminopropyltriethoxysilane in 50 mL 
of 1 mM acetic acid) for 20 min. The solution was decanted, and the mica was rinsed 3 
times with 150 μL of deionized water. After rinsing, the mica stub was dried with 
compressed N2 gas and stored in a desiccator for 1 h. Next, 150 μL of 0.9 μM Aβ sample 
in 20 mM Tris buffer (pH 8.0) was added to the mica and allowed to adsorb for 30 min. 
The sample was then decanted, and the mica stub was rinsed three times with 150 μL of 
deionized water. Finally, the mica stub was dried with compressed N2 gas and stored in a 
desiccator until imaging. The surface topography of each sample was explored by 
 98 
imaging the peptide via a Dimension Icon atomic force microscope (Bruker). 
Measurements were taken under ambient environmental conditions at a constant scan rate 
of 0.5 Hz in tapping mode using a ScanAsyst Air silicon tip (Bruker) on a nitride lever 
(cantilever length, 115 mm; nominal force constant, 0.4 N/m; and resonance frequency, 
70 kHz). The scan size ranged from 5 μm × 5 μm to 1 μm × 1 μm and the resolution was 
kept constant at 512 × 512 data points. AFM scanning was performed using Nanoscope 
5.30r2 software and the images were analyzed using Nanoscope Analysis 1.50 image 
analysis software (Bruker). Multiple areas were imaged for each sample, and whereas 
height, phase, and amplitude data were collected simultaneously, amplitude images were 
used most often in the text to discuss morphology variation between samples.  
 
8.4 Ensemble kinetic simulation (EKS) modeling 
EKS modeling was conducted by Pratip Rana in Dr. Preetam Ghosh’s lab at 
Virginia Commonwealth University.  
Replication phase:  
Monomer addition with O  
𝑂12 + 𝐴
𝑘𝑛𝑢
↔
𝑘𝑛𝑢_
 𝑂13 
𝑂13 + 𝐴
𝑘𝑛𝑢
↔
𝑘𝑛𝑢_
𝑂14 
      ……… 
𝑂23 + 𝐴
𝑘𝑛𝑢
↔
𝑘𝑛𝑢_
 𝐿1 
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Intermediate phase: 
Elongation of L 
𝐿1 +  𝐴 
𝑘𝑙𝑎
↔
𝑘𝑙𝑎_
𝐿2 
𝐿2 +  𝐴 
𝑘𝑙𝑎
↔
𝑘𝑙𝑎_
𝐿3 
      …….. 
𝐿𝑛−23 +  𝐴 
𝑘𝑙𝑎
↔
𝑘𝑙𝑎_
𝑃 
Propagation Phase:  
 Oligomer elongation with L and A 
𝑃 + 𝐿𝑖
𝑘𝑓𝑏1
↔
𝑘𝑓𝑏1_
 𝐹; 𝑖 = 1,2, . . , (𝑛 − 1 − 24) 
𝐹 + 𝐿𝑖
𝑘𝑓𝑏1
↔
𝑘𝑓𝑏1_
 𝐹; 𝑖 = 1,2, . . , (𝑛 − 1 − 24) 
𝑃 + 𝐴
𝑘𝑓𝑏2
↔
𝑘𝑓𝑏2_
 𝐹 
𝐹 + 𝐴
𝑘𝑓𝑏2
↔
𝑘𝑓𝑏2_
  𝐹 
 
 
On Pathway: 
 Nucleation phase: 
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𝐴 + 𝐴
𝑘𝑛𝑢𝑜𝑛
↔
𝑘𝑛𝑢𝑜𝑛__
𝐴2 
… 
𝐴9 + 𝐴
𝑘𝑛𝑢𝑜𝑛
↔
𝑘𝑛𝑢𝑜𝑛_
𝐹𝑜𝑛  
Elongation phase: 
𝐹𝑜𝑛 + 𝐴
𝑘𝑓𝑏𝑜𝑛
↔
𝑘𝑓𝑏𝑜𝑛_
𝐹𝑜𝑛 
The reaction flux of the above reactions can be written as follows (considering F0 and F 
are the same species; O24 and L1 are the same species; Ln-23 and P are the same species): 
Elongation of O 
𝐺𝑖 = 𝑘𝑛𝑢[𝑂12+𝑖−1][𝐴] − 𝑘𝑛𝑢_[𝑂𝑖+12] ;  ∀ 𝑖 ∈ (1, . . ,12)  
Elongation of L 
𝐼𝑖 = 𝑘𝑙𝑎[𝐿𝑖][𝐴] − 𝑘𝑙𝑎_[𝐿𝑖+1] ;  ∀ 𝑖 ∈ (1, . . , 𝑛 − 24)  
 Formation/elongation of F 
   𝐽𝑖
1 = 𝑘𝑓𝑏1[𝐿𝑖][𝑃] − 𝑘𝑓𝑏1_[𝐹]; ∀ 𝑖 ∈ (1, . . , 𝑛 − 24)  
𝐽𝑖
2 = 𝑘𝑓𝑏1[𝐿𝑖][𝐹] − 𝑘𝑓𝑏1_[𝐹]; ∀ 𝑖 ∈ (1, . . , 𝑛 − 24)  
𝐽3 = 𝑘𝑓𝑏2[𝐴][𝑃] − 𝑘𝑓𝑏2_[𝐹]  
𝐽4 = 𝑘𝑓𝑏2[𝐴][𝐹] − 𝑘𝑓𝑏2_[𝐹] 
 
On pathway 
𝐺𝑖
𝑜𝑛 = 𝑘𝑛𝑢𝑜𝑛[𝐴𝑖][𝐴] − 𝑘𝑛𝑢𝑜𝑛_[𝐴𝑖+1] ;  ∀ 𝑖 ∈ (1, . . ,9) 
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𝐼𝑖
𝑜𝑛 = 𝑘𝑓𝑏𝑜𝑛[𝐹][𝐴𝑖] − 𝑘𝑓𝑏𝑜𝑛_[𝐹] ;  ∀ 𝑖 ∈ (1, . . ,9) 
 
Based on this, the ODE formulation of each oligomer will be: 
𝑑𝑂12
𝑑𝑡
= −𝐺1 
𝑑𝑂12+𝑖
𝑑𝑡
= 𝐺𝑖 − 𝐺𝑖+1; ∀ 𝑖 ∈ (1, … , 11) 
𝑑𝐿1
𝑑𝑡
= 𝐺12 − 𝐼1 − 𝐽1
1 − 𝐽1
2  
 
𝑑𝐿𝑖+𝑖
𝑑𝑡
= 𝐼𝑖 − 𝐼𝑖+1 − 𝐽𝑖
1 − 𝐽𝑖
2;  ∀ 𝑖 ∈ (1, … , 𝑛 − 2 24)  
𝑑𝑃
𝑑𝑡
= 𝐼𝑛−1 − 𝑠𝑢𝑚(𝐽𝑖
1) − 𝐽3  
𝑑𝐹
𝑑𝑡
= 𝑠𝑢𝑚(𝐽𝑖
1) + 𝐽3  
𝑑𝐴
𝑑𝑡
= −𝑠𝑢𝑚(𝐺) − 𝑠𝑢𝑚(𝐼) − 𝐽3 − 𝐽4 − 𝑠𝑢𝑚(𝐺𝑖
𝑜𝑛) − 𝐺1
𝑜𝑛−𝐼9
𝑜𝑛  
𝑑𝐴𝑖
𝑑𝑡
= 𝐺𝑖−1
𝑜𝑛 − 𝐺𝑖
𝑜𝑛; ∀ 𝑖 ∈ (2, … ,9) 
𝑑𝐹𝑜𝑛
𝑑𝑡
= 𝐺9
𝑜𝑛 
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Table 8.2 A list of parameters used in the EKS model 
 
 
Parameter estimation: Rate constant estimation for the EKS model was done following 
established methods.35, 124, 130, 148, 149 The above-mentioned differential equations were 
solved using MATLAB, and R2 as well as root mean squared error (RMSE) values 
between the simulated curve and experimental data were calculated for different rate 
constant combinations ranging from 10-5 to 109 in multiples of 10. Next, the estimated 
rate constants were fine-tuned to obtain a better correspondence with the experimental 
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data (see Chapter IV for a list of final rate constants). The size of the intermediate (P) 
was similarly varied from 36-120mers and corresponding R2 and RMSE values were 
calculated.  
To achieve global fits for both the ThT data and monomer/oligomer/fibril 
concentration data, a two-step method was used. Here, the minimum R2 values and 
maximum RMSE values for the fitted curves were considered, instead of an average, 
which can erroneously give higher confidence in the results. To ensure both a global fit 
with ThT data, and a good correspondence with quantitative data on the species during 
propagation, cutoffs on the allowable minimum R2 and maximum RMSE values were 
defined. A lower RMSE cut-off ensures a better global fit with ThT and concentration 
plots. Hence, an RMSE cut-off of 0.11 with the ThT curves for gateways 48-84 was used. 
It is worth noting that the same cut-off did not produce allowable rate constant estimates 
for gateways 36 and 96-120. In the latter cases, the RMSE cut-offs were increased to 
generate the global fitting parameters reported in Chapter IV. Next, all rate constant 
combinations that achieved the cutoffs for the ThT fits were considered. These rate 
constant combinations were then used to fit with the concentration curves to identify the 
‘goodness-of-fit’. Overall, this two-step model first finds allowable rate constants that 
meet the cutoff requirements for fitting the ThT data and then identifies the best rate 
constants from this range to fit with the quantitation plots.  
 
Mapping concentration values from simulation to experimental plots: The contributions 
of oligomers to the ThT intensity was considered to be proportional to their size, whereas 
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the fibril contribution to the ThT intensity was taken as p. Thus, the ThT signal 
contribution from the final fibril (signal') could be written as: 
𝑠𝑖𝑔𝑛𝑎𝑙′ = [𝐹] ∗ 𝑝 
where, [F] is the concentration of final fibril.  
Similarly, the ThT signal contribution from the intermediate fibrils (signal˝) could be 
written as: 
𝑠𝑖𝑔𝑛𝑎𝑙′′ = ∑([𝐿𝑖]
𝑛−1
𝑖=2
 
Hence, the total simulated ThT signal contribution for both final and intermediate fibrils 
became:  
𝑠𝑖𝑔𝑛𝑎𝑙 = 𝑠𝑖𝑔𝑛𝑎𝑙′ + 𝑠𝑖𝑔𝑛𝑎𝑙′′ 
 
For the fits with concentration data, monomer and oligomer concentration fractions from 
the simulation data were defined as: 
𝑚𝑜𝑛𝑜𝑚𝑒𝑟_𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 = [𝐴]/[𝑝𝑟𝑜𝑡𝑒𝑖𝑛_𝑡𝑜𝑡𝑎𝑙] 
𝑜𝑙𝑖𝑔𝑜𝑚𝑒𝑟_𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛
= (𝑖 ∗ ∑ 𝑂𝑖 + (23 + 𝑖) ∗ ∑ 𝐿𝑖 + 𝑛 ∗ 𝑃 + 𝑖 ∗ ∑ 𝐴𝑖
𝑜𝑛)/[𝑝𝑟𝑜𝑡𝑒𝑖𝑛_𝑡𝑜𝑡𝑎𝑙] 
9
𝑖=2
𝑛−24
𝑖=1
23
𝑖=12
 
However, predicting the concentration of fibrils from simulation data was challenging as 
the fibrils are considered a single species (F) without distinguishing their individual sizes; 
this was done to keep the models tractable. Hence, the concentration of F was calculated 
in an indirect way as follows: 
[F]=1 - monomer_fraction - oligomer_fraction  
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8.5 Cell culture methods 
Cell culture experiments were conducted by Dr. Kayla M. Pate in the lab of Dr. 
Melissa A. Moss at The University of South Carolina. Human neuroblastoma SH-SY5Y 
cells (American Type Culture Collection, Manassas, VA) were maintained in a 1:1 
mixture of Ham’s F12K medium and DMEM (F12K/DMEM) containing 10% FBS. 
Medium was supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. All 
cultures were maintained at 37 °C in a humid atmosphere of 5% CO2 and 95% air.  
 
8.5.1 Cellular apoptosis 
To assess the ability of LFAOs to induce apoptosis, a TUNEL system (Promega, 
Madison, WI) was used. Prior to experimentation, SH-SY5Y cells were seeded at a 
density of 1 × 106 cells/well onto 22 × 22 mm glass coverslips and maintained for 24 h in 
F12K/DMEM media containing 10% FBS. For cell treatment, 10 μM Aβ was diluted in 
F12K/DMEM containing 1% FBS to final concentrations of 0.01, 0.1, and 1 μM and 
added to cells for 24 h. Cells treated with buffer equivalent or 25 μM H2O2 served as 
negative and positive controls, respectively. Following 24 h incubation (37 °C, 5% CO2), 
treatment was removed, and cells were fixed with 4% paraformaldehyde in PBS (10 min, 
25 °C). Cells were then permeabilized with 0.1% Triton X-100, 0.01 M glycine in PBS 
(10 min, 25 °C) and washed twice with PBS (10 min, 25 °C). Cells were then placed in 
100 μL of equilibration buffer (10 min, 25 °C) before incubation in 50 μL of rTdT 
incubation buffer (1 h, 37 °C), which labels the DNA strand breaks with fluorescein-12-
dUTP. After incubation, labeling was halted by adding 17 mM saline-sodium citrate (pH 
7.0) containing 150 mM NaCl (15 min, 25 °C), and cells were washed three times with 
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PBS (5 min, 25 °C). Labeled cells were mounted onto glass slides using Fluoroshield 
containing DAPI for nuclear staining. Cells were imaged under a Nikon Eclipse 80i 
fluorescent microscope using a 40X objective. For each slide, three or four different 
fields were captured for analysis. For each field, both a DAPI image and TUNEL image 
were acquired. Custom MATLAB (MathWorks, Natick, MA)150 functions were 
developed to determine the fraction of apoptotic cells present for each sample. From 
DAPI images, the total number of cells was assessed using MATLAB to identify pixel 
intensity regions. The boundary of these regions was then increased in a stepwise manner 
until the pixel intensity of the boundary fell below the threshold, indicating that the 
boundary of the nuclei had been reached. Once all nuclei boundaries were determined, 
the total number of nuclei present was recorded by MATLAB. Using the nuclei 
boundaries determined from the DAPI images, the average TUNEL pixel intensity within 
each nucleus was determined from the corresponding TUNEL image. Cells exhibiting an 
average TUNEL pixel intensity above 20 were deemed apoptotic. The fraction of 
apoptotic cells was defined as the number of apoptotic cells divided by the total number 
of cells. For each treatment 300-600 cells were analyzed.  
 
8.5.2 Caspase activation 
An Image-iT LIVE Green Poly Caspases detection kit (Life Technologies, 
Carlsbad, CA) was used to determine if caspase activation was the driving force behind 
LFAO-induced cellular apoptosis. SH-SY5Y cells were prepared and treated for 24 h 
with 0.01, 0.1, and 1 μM LFAOs, as described above. Cells treated with buffer equivalent 
or 2 U/μL TNF-α served as negative and positive controls, respectively. Following 24 h 
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incubation (37 °C, 5% CO2), treatment was removed, and cells were stained using a 
FLICA reagent for detection of a wide range of active caspase enzymes (caspase-1, -3, -
4, -5, -6, -7, -8, and -9) and using Hoechst 33342 for labeling of nuclei. Cells were rinsed 
with phenol red free F12K/DMEM containing 1% FBS (PRF F12K/DMEM, 1% FBS) 
and incubated (37 °C, 5% CO2) for 1 h with 1X FLICA stain diluted in PRF 
F12K/DMEM, 1% FBS. After incubation, the stain was removed, and cells were washed 
twice with PRF F12K/DMEM, 1% FBS before 10 min incubation (37 °C, 5% CO2) with 
Hoechst 33342 stain (diluted 1:1000 in PRF F12K/ DMEM, 1% FBS). The cells were 
then washed twice and mounted to slides using a fixative solution. Slides were imaged 2 
h after staining to avoid signal loss using a Nikon Eclipse 80i fluorescent microscope 
with a 40X objective. For each slide, three to five different fields were captured for 
analysis. For each field, both a Hoechst image and a FLICA image were acquired. 
Custom MATLAB functions were developed to determine the fraction of caspase active 
cells. From Hoechst images, the total number of cells was assessed as described above for 
DAPI images. From corresponding FLICA images and using the nuclei boundaries 
determined from the Hoechst images as a reference, MATLAB was used to determine the 
average FLICA pixel intensity within a region that included both the nucleus and a 
specified region outside the nucleus, which accounts for caspase staining that can reside 
within both the nucleus and cytoplasm. Cells exhibiting an average FLICA pixel intensity 
above 5 were deemed caspase active. For each treatment, 200-600 cells were analyzed.  
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8.6 Transgenic mice methods 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Florida, and experiments were conducted by 
Franklin Burg in Dr. Yona Levites’ lab. All methods and procedures were performed in 
accordance to the guidelines and regulations. APP transgenic TgCRND8125 were bred in-
house. Neonatal ICV injections with 1–4 μL of Aβ monomers, Fon aggregates, or O/Ls 
(10 μM) were performed similarly to described before.
151
  
 
8.6.1 Aβ ELISA 
Mouse brains were sagittally dissected and left hemisphere was used for protein 
extraction using a sequential extraction protocol of RIPA buffer, 2% SDS and 70% 
formic acid as described previously.152 All ELISA results were analyzed using SoftMax 
Pro software (Molecular Device).  
 
8.6.2 Immunohistochemical imaging and image processing 
Following tissue harvesting, the right hemisphere was formalin fixed, paraffin 
embedded and used for immunohistochemistry. Immunohistochemical staining was done 
using anti-pan-Aβ mAb5Biotin antibody (1:1500)152, (biotinilated antibody was chosen in 
order to eliminate mouse IgG background staining interference). Immunohistochemically 
stained sections were captured using the Scanscope XT image scanner (Aperio) and 
analyzed using ImageScope program. Aβ plaque burden was calculated using the Positive 
Pixel Count program (Aperio). At least three sections per sample, 30 μm apart, were 
averaged by a blinded observer to calculate plaque burden. For evaluation of CAA, 
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sections stained with anti-pan-Aβ mAb5Biotin antibody were evaluated by a blind 
observer and blood vessels scored for presence of positive staining. 0 – no staining, 1–
25% stained, 2–50% of the vessel has amyloid, 3 – entire vessel is stained. Vessels that 
received a score of 2 or 3 were counted in three sections per sample. 
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